KASID
Original article
- Page Path
- HOME > Article category > Original article
Original Articles
- Inflammatory Bowel Diseases
- Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
- Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul
- Intest Res 2021;19(1):83-94. Published online December 31, 2020
- DOI: https://doi.org/10.5217/ir.2019.09160
-
Abstract
PDF
Supplementary Material
PubReader
ePub - Background/Aims
The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in the subgroup of patients from Asian countries.
Methods
During the induction phase (doses at day 1, 15), clinical remission, enhanced clinical response, and change in C-reactive protein at 6 weeks; during the maintenance phase, clinical remission, enhanced clinical response, glucocorticoid-free remission and durable clinical remission at 52 weeks, were the efficacy outcomes of interest. Efficacy and safety of vedolizumab compared to placebo were assessed in Asian countries (Hong Kong, India, Malaysia, Singapore, South Korea, and Taiwan) using descriptive analyses.
Results
During the induction phase, in Asian countries (n = 51), 14.7% of the vedolizumab-treated patients achieved clinical remission at week 6 compared to none with placebo (difference, 14.7%; 95% confidence interval, 15.8%–43.5%). In non-Asian countries (n = 317), the remission rate at week 6 with vedolizumab was 14.5%. During maintenance, in Asian countries, clinical remission rates at 52 weeks with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks and placebo were 41.7%, 36.4%, and 0%, respectively; while enhanced clinical response rates were 41.7%, 63.6%, and 42.9%, respectively. During induction, 39.7% of patients with vedolizumab experienced an adverse event compared to 58.8% of patients with placebo, and vedolizumab was generally well-tolerated.
Conclusions
This post-hoc analysis demonstrates the treatment effect and safety of vedolizumab in moderateto-severely active CD in patients from Asian countries. -
Citations
Citations to this article as recorded by
- Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Laurent Peyrin‐Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Marc Ferrante, Jordi Guardiola, Jørgen Jahnsen, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Philip J Smith, Taek Kwon, Jeeyoung Kim, Sangwook Yoon, Dong-Hyeon Kim
BMC Gastroenterology.2024;[Epub] CrossRef - A Review on Nanosystem-Based Delivery of Tofacitinib for Enhanced Treatment of Autoimmune Diseases and Inflammation
Thi-Thao-Linh Nguyen, Van-An Duong
BioNanoScience.2024; 14(2): 2048. CrossRef - Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun‐Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk‐Kyun Yang, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1539. CrossRef - The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef - Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study
Wei-Chen Lin, Wei-Chen Tai, Chung-Hsin Chang, Chia-Hung Tu, I-Che Feng, Ming-Jium Shieh, Chen-Shuan Chung, Hsu-Heng Yen, Jen-Wei Chou, Jau-Min Wong, Yu-Hwa Liu, Tien-Yu Huang, Chiao-Hsiung Chuang, Tzung-Jiun Tsai, Feng-Fan Chiang, Chien-Yu Lu, Wen-Hung Hs
Inflammatory Bowel Diseases.2023; 29(11): 1730. CrossRef - Factors associated with the prescription of probiotics in patients with inflammatory bowel disease: a cross-sectional study
Joo Kyung Kim, Jae Hee Cheon
Journal of Yeungnam Medical Science.2023; 40(1): 37. CrossRef - Concomitant ankylosing spondylitis can increase the risk of biologics or small molecule therapies to control inflammatory bowel disease
Yu Kyung Jun, Hyuk Yoon, Seong-Joon Koh, A Hyeon Kim, Kwang Woo Kim, Jun Won Park, Hyun Jung Lee, Hyoun Woo Kang, Jong Pil Im, Young Soo Park, Joo Sung Kim
Intestinal Research.2023; 21(2): 244. CrossRef - The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Myeong Geun Choi, Byong Duk Ye, Suk-Kyun Yang, Tae Sun Shim, Kyung-Wook Jo, Sang Hyoung Park
Journal of Korean Medical Science.2022;[Epub] CrossRef - Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Laurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, Silvio Danese, Jordi Guardiola, Jørgen Jahnsen, Charles Lees, Edouard Louis, Milan Lukáš, Walter Reinisch, Xavier Roblin, Minyoung Jang, Han Geul Byun, Dong-Hyeon Kim, Sung Jeong Lee, Raja Atrey
BMC Gastroenterology.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Prevention of postoperative recurrence in Crohn’s disease: the never-ending story
Jung-Bin Park, Sang Hyoung Park
Intestinal Research.2022; 20(3): 279. CrossRef - Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Current status of inflammatory bowel diseases in Korea
Suk-Kyun Yang
Journal of the Korean Medical Association.2021; 64(9): 572. CrossRef
- Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn’s disease and ulcerative colitis included in randomised controlled trials
- 7,977 View
- 171 Download
- 16 Web of Science
- 16 Crossref
- Inflammatory Bowel Diseases
- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
- Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, Umesh Jalihal, Deng-Chyang Wu, Dirk Demuth, Dirk Lindner, Shashi Adsul
- Intest Res 2021;19(1):71-82. Published online September 4, 2020
- DOI: https://doi.org/10.5217/ir.2019.09159
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The efficacy and safety of vedolizumab in moderate to severely active ulcerative colitis (UC) have been demonstrated in the GEMINI 1 study (NCT00783718). This post-hoc exploratory analysis sought to establish the efficacy and safety of vedolizumab in a subgroup of patients from Asian countries with UC from GEMINI 1.
Methods
Efficacy outcomes of interest were clinical response, clinical remission and mucosal healing at week 6 (induction phase); and clinical remission, durable clinical response, durable clinical remission, mucosal healing and glucocorticoid-free remission at week 52 (maintenance phase). Differences in outcome rates between vedolizumab and placebo in Asian countries (Hong Kong, India, Malaysia, Singapore, South Korea, and Taiwan) were assessed using descriptive analyses, and efficacy and safety compared between Asian and non-Asian countries.
Results
During induction, in Asian countries (n = 58), clinical response rates at week 6 with vedolizumab and placebo were 55.2% and 24.1%, respectively (difference 31.0%; 95% confidence interval: 7.2%–54.9%). In non-Asian countries (n = 316), response rates at week 6 with vedolizumab and placebo were 45.9% and 25.8%, respectively. During maintenance, in Asian countries, clinical remission rates at 52 weeks with vedolizumab administered every 8 weeks, vedolizumab administered every 4 weeks and placebo were 9.1%, 36.8%, and 31.6%, respectively; corresponding rates for mucosal healing were 45.5%, 47.4%, and 47.4%, respectively. Vedolizumab was well-tolerated; adverse event frequency was comparable in Asian and non-Asian countries.
Conclusions
In patients from Asian countries, the efficacy and safety of vedolizumab in treatment of UC were broadly consistent with that in the overall study population. -
Citations
Citations to this article as recorded by- Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
Kyuwon Kim, Jae Jun Park, Hyuk Yoon, Jun Lee, Kyeong Ok Kim, Eun Sun Kim, Su Young Kim, Sun‐Jin Boo, Yunho Jung, Jun Hwan Yoo, Sung Wook Hwang, Sang Hyoung Park, Suk‐Kyun Yang, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 59(12): 1539. CrossRef - Clinical performance of fecal calprotectin, lactoferrin, and hemoglobin for evaluating the disease activity of IBD and detecting colorectal tumors
Tsukasa Yamakawa, Takakazu Miyake, Yoshihiro Yokoyama, Tomoe Kazama, Yuki Hayashi, Daisuke Hirayama, Shinji Yoshii, Hiro‐o Yamano, Satoshi Takahashi, Hiroshi Nakase
JGH Open.2024;[Epub] CrossRef - The role and prospect of tofacitinib in patients with ulcerative colitis
Jun Lee
Intestinal Research.2023; 21(1): 168. CrossRef - The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef - Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China
Kaituo Huang, Jing Liu, Wenhao Xia, Chuwen Tian, Lingya Yao, Qian Cao, Haotian Chen
Frontiers in Pharmacology.2023;[Epub] CrossRef - The effectiveness and safety of vedolizumab induction for moderate to severe ulcerative colitis for Asia patient: A real practice observational study
Chia-Jung Kuo, Puo-Hsien Le, Wei-Chen Tai, Keng-Liang Wu, Hsu-Heng Yen, Chih-Wei Yen, Shui-Yi Tung, Chen-Shuan Chung, Ming-Yao Su, Cheng-Tang Chiu
Journal of the Formosan Medical Association.2022; 121(9): 1689. CrossRef - Vedolizumab does not increase perioperative surgical complications in patients with inflammatory bowel disease, cohort study
Vitaliy Y. Poylin, Jose Cataneo Serrato, Jonathan Pastrana Del Valle, Joseph D. Feuerstein
Intestinal Research.2022; 20(1): 72. CrossRef - Comparative effectiveness of second-line biological therapies for ulcerative colitis and Crohn’s disease in patients with prior failure of anti-tumour necrosis factor treatment
Hye Kyung Hyun, Hyun-Soo Zhang, Jongwook Yu, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
BMC Gastroenterology.2022;[Epub] CrossRef - The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Myeong Geun Choi, Byong Duk Ye, Suk-Kyun Yang, Tae Sun Shim, Kyung-Wook Jo, Sang Hyoung Park
Journal of Korean Medical Science.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef - Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Combination of vedolizumab and immunomodulators in ulcerative colitis
P Pinton
Journal of Gastroenterology and Hepatology.2021; 36(12): 3556. CrossRef - Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center
Ann-Lorie Gagnon, William Beauchesne, Laurence Tessier, Charles David, Djamal Berbiche, Alexandre Lavoie, Alban Michaud-Herbst, Karine Tremblay
Crohn's & Colitis 360.2021;[Epub] CrossRef - Vedolizumab in Inflammatory Bowel Disease: West versus East
Prasanta Debnath, Pravin M. Rathi
Inflammatory Intestinal Diseases.2021; 6(1): 1. CrossRef
- Application of clinical decision support tools for predicting outcomes with vedolizumab therapy in patients with inflammatory bowel disease: A KASID multicentre study
- 7,171 View
- 253 Download
- 17 Web of Science
- 18 Crossref
- Inflammatory Bowel Diseases
- The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
- Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, Jung Rock Moon, Tae Hee Lee, Jae Young Jang, Jun-Hyung Cho, Jun Seok Park, Heesu Park, Ki-hun Lee, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Suyeon Park
- Intest Res 2021;19(1):62-70. Published online May 8, 2020
- DOI: https://doi.org/10.5217/ir.2019.09156
-
Abstract
PDFPubReaderePub
- Background/Aims
Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) can serve as biomarkers for diagnosing and assessing disease activity in ulcerative colitis (UC). We investigated their clinical significance in UC.
Methods
We analyzed 48 patients with UC who underwent measurement of fecal calprotectin (FC) and endoscopy and 96 age- and sex-matched healthy controls. NLR and PLR were compared between the patients and healthy controls. The endoscopic activity was divided into 2 groups: group 1 (mild to moderate inflammation) and group 2 (severe inflammation) according to the Mayo endoscopic subscore in UC.
Results
To diagnose UC, the optimal cutoff of NLR and PLR was 2.26 (sensitivity 54.2%; specificity 90.6%; positive likelihood ratio 5.778, 95% confidence interval [CI] 2.944–11.339; area under the curve [AUC] 0.774, 95% CI, 0.690–0.859) and 179.8 (sensitivity 35.4%; specificity 90.6%; positive likelihood ratio 3.778, 95% CI 1.821–7.838; AUC 0.654, 95% CI 0.556–0.753), respectively. The optimal cutoff to differentiate group 1 and group 2 was 3.44, 175.9, and 453 µg/g for NLR, PLR, and FC, respectively (sensitivity, 63.6% vs. 90.9% vs. 81.8%; specificity, 81.1% vs. 78.4% vs. 73.0%; positive likelihood ratio, 3.364 vs. 4.205 vs. 3.027; AUC, 0.714 vs. 0.897 vs. 0.813). PLR had the highest AUC and positive likelihood ratio.
Conclusions
NLR and PLR help differentiate patients with UC from healthy controls. NLR, PLR, and FC indicate endoscopic activity and may reflect intestinal mucosal conditions. -
Citations
Citations to this article as recorded by- Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment
Kairong Su, Sinan Xiao, Mei Wang, Kairuo Wang, Qing Fan, Sumei Sha, Yongli Cheng, Xin Liu, Haitao Shi
Journal of Inflammation Research.2025; Volume 18: 589. CrossRef - The ability of C-reactive protein-albumin ratio to predict disease activity in ulcerative colitis
Ibrahimhalil Dusunceli, Zeynep Gok Sargin, Umut Celik, Fatih Sargin
Biomarkers in Medicine.2025; 19(4): 113. CrossRef - Exploring the utility of cellular indices in the diagnosis of ulcerative colitis
Julio César Moreno Alfonso, Sharom Barbosa-Velásquez, Carlos Delgado-Miguel, Ada Molina Caballero, Sara Hernández-Martín, Alberto Pérez Martínez, María Concepción Yárnoz Irazábal
Gastroenterología y Hepatología.2025; : 502349. CrossRef - Clinical relevance of inflammatory markers in the evaluation of severity of ulcerative colitis: A retrospective study
Tao He, Lian-Qiang Song, Xiao-Yu Weng, Peng Pan, Hui Ding, Mei-Qin Liu, Shi-Lin Qiu, Shan-Ming Sun
Open Life Sciences.2025;[Epub] CrossRef - Development and validation of a nomogram for predicting endoscopic healing in crohn’s disease patients receiving infliximab treatment
Lixuan Li, Ting Feng, Xuanzhi Huang, Xiaoman Zu, Minhu Chen, Yun Qiu
BMC Gastroenterology.2025;[Epub] CrossRef - Ischemia-modified albumin: a novel blood marker of endoscopic mucosal healing in inflammatory bowel disease
Seung Bum Lee, Hyun-Ki Kim, Sang Hyuk Park, Ji-Hun Lim, Sang Hyoung Park
Intestinal Research.2024; 22(1): 75. CrossRef - Evaluation of the prognostic nutritional index (PNI) as a tool for assessing disease activity in rheumatoid arthritis patients
Nuran Öz, Halise Hande Gezer, Selin Cilli Hayıroğlu, Mehmet Tuncay Duruöz
Clinical Rheumatology.2024; 43(5): 1461. CrossRef - Progress in Biomarkers of Inflammatory Bowel Disease
舒 陈
Advances in Clinical Medicine.2024; 14(03): 1418. CrossRef - Fecal calprotectin and platelet count predict histologic disease activity in pediatric ulcerative colitis: results from a projection-predictive feature selection
B. Schiller, E. Wirthgen, F. Weber, S. Schiller, M. Radke, M. Claßen, J. Däbritz, S. Buderus, P. Bufler, J. Däbritz, S. Dammann, J. de Laffolie, M. Friedt, A. Hauer, K. M. Keller, A. Krahl, M. Laaß, T. Lang, C. Posovszky, B. Rodeck, S. Trenkel
European Journal of Pediatrics.2024; 183(8): 3277. CrossRef - Association of Hemogram Parameters with Body Mass Index in Knee Osteoarthritis
Koksal Gundogdu, Gülşah Gündoğdu, Alper Kurtoğlu
Online Türk Sağlık Bilimleri Dergisi.2024; 9(3): 202. CrossRef - Systemic Immune-Inflammation Index: Unveiling the Diagnostic Potential in Ulcerative Colitis through a Comprehensive Systematic Review and Meta-Analysis
Anas Elgenidy, Omar Alomari, Tasbih Emad, Sara K. Kamal, Islam E. Al Ghanam, Aya Sherif, Mohammed Al-mahdi Al-kurdi, Abdallah A. Helal, Yusof Mohamed Omar, Mohamed Rafiek Ramadan
Gastroenterology & Endoscopy.2024;[Epub] CrossRef - CRP/Albumin Ratio as Potential Indicator for Assessment of Disease Activity in Inflammatory Bowel Disease Patients
Fatma Abdel-Kader Attia Mohamed, Eman Refaat Youness, Marwa M. Hassan, Nesma Hassan Hasanein Ashour
Biomedical and Pharmacology Journal.2024; 17(4): 2683. CrossRef - Cytomegalovirus Reactivation in Ulcerative Colitis Patients: Early Indicators
LN Altunal, AS Ozel, C AK
Nigerian Journal of Clinical Practice.2023; 26(6): 765. CrossRef - The role of platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in the diagnosis and severity of inflammatory bowel disease in children
Arefeh Zahmatkesh, Mohammad Hassan Sohouli, Seyed Mahmoud Eshagh Hosseini, Pejman Rohani
European Journal of Pediatrics.2023; 182(9): 4263. CrossRef - Ülseratif kolit aktivitesi ve şiddetinin invaziv olmayan biyobelirteçler ile değerlendirilmesi
İlyas TENLİK, Orhan COŞKUN, Mustafa ÇAPRAZ, Volkan GÖKBULUT, Ömer ÖZTÜRK
Akademik Gastroenteroloji Dergisi.2023; 22(2): 59. CrossRef - Interrelation of Hypoxia-Inducible Factor-1 Alpha (HIF-1 α) and the Ratio between the Mean Corpuscular Volume/Lymphocytes (MCVL) and the Cumulative Inflammatory Index (IIC) in Ulcerative Colitis
Ioan Sabin Poenariu, Lidia Boldeanu, Bogdan Silviu Ungureanu, Daniel Cosmin Caragea, Oana Mariana Cristea, Vlad Pădureanu, Isabela Siloși, Anca Marinela Ungureanu, Răzvan-Cristian Statie, Alina Elena Ciobanu, Dan Ionuț Gheonea, Eugen Osiac, Mihail Virgil
Biomedicines.2023; 11(12): 3137. CrossRef - Effect of ozone therapy on neutrophil/lymphocyte, platelet/lymphocyte ratios, and disease activity in ankylosing spondylitis
Habibe İnci, Fatih İnci
Medical Gas Research.2023; 13(2): 53. CrossRef - Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
Intestinal Research.2022; 20(1): 101. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - The Usefulness of Extended Inflammation Parameters and Systemic Inflammatory Response Markers in the Diagnostics of Autoimmune Hepatitis
Weronika Domerecka, Anna Kowalska-Kępczyńska, Iwona Homa-Mlak, Agata Michalak, Radosław Mlak, Marcin Mazurek, Halina Cichoż-Lach, Teresa Małecka-Massalska
Cells.2022; 11(16): 2554. CrossRef - Complete Blood Count-Derived Inflammatory Markers Changes in Dogs with Chronic Inflammatory Enteropathy Treated with Adipose-Derived Mesenchymal Stem Cells
José Ignacio Cristóbal, Francisco Javier Duque, Jesús Usón-Casaús, Rafael Barrera, Esther López, Eva María Pérez-Merino
Animals.2022; 12(20): 2798. CrossRef - Evaluation of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as potential markers for ulcerative colitis: a retrospective study
Wan Feng, Yajun Liu, Lei Zhu, Luzhou Xu, Hong Shen
BMC Gastroenterology.2022;[Epub] CrossRef - Association of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio with Diabetic Kidney Disease in Chinese Patients with Type 2 Diabetes: A Cross-Sectional Study
Lan Li, Qing Shen, Sijie Rao
Therapeutics and Clinical Risk Management.2022; Volume 18: 1157. CrossRef - Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Chronic Plaque Psoriasis
Sudeshna Mondal, Samudra Guha, Abanti Saha, Loknath Ghoshal, Debabrata Bandyopadhyay
Indian Journal of Dermatology.2022; 67(4): 477. CrossRef - Correlations of disease severity and age with hematology parameter variations in patients with COVID‐19 pre‐ and post‐treatment
Juanying Liang, Shaoyun Nong, Liejun Jiang, Xiaowei Chi, Dewu Bi, Jun Cao, Lida Mo, Xiaolu Luo, Huayi Huang
Journal of Clinical Laboratory Analysis.2021;[Epub] CrossRef - Elevated systemic immune inflammation index level is associated with disease activity in ulcerative colitis patients
Yiyi Xie, Tingting Zhuang, Ying Ping, Yingzhi Zhang, Xuchu Wang, Pan Yu, Xiuzhi Duan
Clinica Chimica Acta.2021; 517: 122. CrossRef - Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
Ho Min Yong, Sung-Jo Park, Seong Ran Jeon, Heesu Park, Hyun Gun Kim, Tae Hee Lee, Junseok Park, Jin-Oh Kim, Joon Seong Lee, Bong Min Ko, Hyeon Jeong Goong, Suyeon Park
Medicine.2021; 100(34): e27065. CrossRef - Inflammatory Bowel Disease and Neutrophil–Lymphocyte Ratio: A Systematic Scoping Review
Blake O. Langley, Sara E. Guedry, Joshua Z. Goldenberg, Douglas A. Hanes, Jennifer A. Beardsley, Jennifer Joan Ryan
Journal of Clinical Medicine.2021; 10(18): 4219. CrossRef - Lymphocyte-to-Monocyte Ratio as a Marker for Endoscopic Activity in Ulcerative Colitis
Natsuki Ishida, Satoru Takahashi, Yusuke Asai, Takahiro Miyazu, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Moriya Iwaizumi, Yasushi Hamaya, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Immuno.2021; 1(4): 360. CrossRef - Peripheral blood neutrophil-to-lymphocyte ratio in inflammatory bowel disease and disease activity: A meta-analysis
Wei Fu, Hu Fu, Weixia Ye, Yinsuo Han, Xianqiang Liu, Sirui Zhu, Hongmin Li, Rong Tang, Qin Wang
International Immunopharmacology.2021; 101: 108235. CrossRef - Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Noninvasive Predictors of the Therapeutic Outcomes of Systemic Corticosteroid Therapy in Ulcerative Colitis
Katsuya Endo, Tomonori Satoh, Yuki Yoshino, Shiho Kondo, Yoko Kawakami, Tomofumi Katayama, Yoshiteru Sasaki, Atsuko Takasu, Takayuki Kogure, Morihisa Hirota, Takayoshi Meguro, Kennichi Satoh
Inflammatory Intestinal Diseases.2021; 6(4): 218. CrossRef - Association between platelet count and mucosal healing in Japanese patients with ulcerative colitis: a cross-sectional study
Shinya Furukawa, Sen Yagi, Kana Shiraishi, Kenichirou Mori, Tomoyuki Ninomiya, Keitarou Kawasaki, Yuji Mizukami, Seiyuu Suzuki, Masayoshi Uraoka, Naozumi Shibata, Sanae Nakamura, Satoshi Imamine, Hidehiro Murakami, Katsuhisa Ohashi, Masamoto Torisu, Aki H
BMC Gastroenterology.2020;[Epub] CrossRef
- Predictive Value of Albumin to Fibrinogen Ratio and CALLY Index for Diagnosis of Ulcerative Colitis and Mucosal Healing After Vedolizumab Treatment
- 7,673 View
- 233 Download
- 28 Web of Science
- 32 Crossref
- Inflammatory Bowel Diseases
- Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
- Toshifumi Hibi, Isao Kamae, Philippe Pinton, Lyann Ursos, Ryuichi Iwakiri, Greg Hather, Haridarshan Patel
- Intest Res 2021;19(1):53-61. Published online April 22, 2020
- DOI: https://doi.org/10.5217/ir.2019.09146
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Several biologic therapies are approved in Japan to treat moderately to severely active ulcerative colitis (UC), but there are no published comparative efficacy studies in a Japanese population. We compared the efficacy of biologics approved in Japan (adalimumab, infliximab, golimumab, and vedolizumab) for treating biologic-naïve patients with UC at their approved doses.
Methods
A targeted literature review identified 4 randomized controlled trials of biologics for UC in biologicnaïve Japanese patients. For each study, efficacy outcome data from induction (weeks 6–12) and maintenance (weeks 30–60) treatment were extracted for analysis. Treatment effects on clinical response, clinical remission, and mucosal healing relative to the average placebo results across all trials were estimated using network meta-analyses followed by transformation into probabilities and odds ratios (OR).
Results
At the end of induction, the likelihood of clinical response and clinical remission was highest with infliximab (OR: 2.12 and 2.35, respectively) and vedolizumab (OR: 2.10 and 2.32, respectively); the likelihood of mucosal healing was highest with infliximab (OR: 2.24) and adalimumab (OR: 1.86). During maintenance, the likelihood of clinical response and clinical remission was highest with vedolizumab (OR: 6.44 and 4.68, respectively) and golimumab (OR: 5.13 and 3.84, respectively); the likelihood of mucosal healing was significantly higher than placebo with all biologics.
Conclusions
All active treatments were efficacious compared with placebo. Infliximab and vedolizumab had the highest odds for induction of clinical response, remission, and mucosal healing. Golimumab and vedolizumab had numerically higher odds of achieving efficacy outcomes in the maintenance phase. -
Citations
Citations to this article as recorded by- Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
Health Science Reports.2024;[Epub] CrossRef - Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
Ken Takeuchi, Tadakazu Hisamatsu, Hiroshi Nakase, Katsuyoshi Matsuoka, Michael Keating, Hirotoshi Yuasa, Motoki Oe, Shoko Arai, Rafal Mazur, Toshifumi Hibi
Digestion.2024; : 1. CrossRef - Selection of anti-cytokine biologics by pretreatment levels of serum leucine-rich alpha-2 glycoprotein in patients with inflammatory bowel disease
Takahiro Amano, Takeo Yoshihara, Shinichiro Shinzaki, Yuko Sakakibara, Takuya Yamada, Naoto Osugi, Satoshi Hiyama, Yoko Murayama, Koji Nagaike, Hideharu Ogiyama, Toshio Yamaguchi, Yuki Arimoto, Ichizo Kobayashi, Shoichiro Kawai, Satoshi Egawa, Takashi Kiz
Scientific Reports.2024;[Epub] CrossRef - The role and prospect of tofacitinib in patients with ulcerative colitis
Jun Lee
Intestinal Research.2023; 21(1): 168. CrossRef - Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting
Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im
Intestinal Research.2023; 21(3): 353. CrossRef - Diagnosis, management, and prevention of infectious complications in inflammatory bowel disease: variations among Asian countries
Ji Eun Baek, Sung Wook Hwang
Intestinal Research.2023; 21(3): 277. CrossRef - Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
Soo-Young Na
The Korean Journal of Medicine.2023; 98(5): 223. CrossRef - Biomarker dynamics during infliximab salvage for acute severe ulcerative colitis: C-reactive protein (CRP)-lymphocyte ratio and CRP-albumin ratio are useful in predicting colectomy
Danny Con, Bridgette Andrew, Steven Nicolaides, Daniel R van Langenberg, Abhinav Vasudevan
Intestinal Research.2022; 20(1): 101. CrossRef - How to Choose the Biologic Therapy in a Bio-naïve Patient with Inflammatory Bowel Disease
Viviana Laredo, Carla J. Gargallo-Puyuelo, Fernando Gomollón
Journal of Clinical Medicine.2022; 11(3): 829. CrossRef - Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
Journal of Personalized Medicine.2022; 12(3): 507. CrossRef - The Prognostic Value of Residual Nonrectal Inflammation in Ulcerative Colitis
Eun Ae Kang
Gut and Liver.2022; 16(3): 487. CrossRef - Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef - Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Gut and Liver.2022; 16(5): 764. CrossRef - Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Byung Chul Jin, Hee Jin Moon, Sang Wook Kim
The Korean Journal of Gastroenterology.2022; 80(2): 72. CrossRef - Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
Jae Song Kim, Min Jung Geum, Eun Sun Son, Yun Mi Yu, Jae Hee Cheon, Kyeng Hee Kwon
Gut and Liver.2022; 16(5): 736. CrossRef - Viral Hepatitis in Patients with Inflammatory Bowel Disease
Seung Hwan Shin, Sang Hyoung Park
The Korean Journal of Gastroenterology.2022; 80(2): 51. CrossRef - Treatment of inflammatory bowel diseases: focusing on biologic agents and new therapies
Hyo Yeop Song, Geom Seog Seo
Journal of the Korean Medical Association.2021; 64(9): 605. CrossRef - Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef
- Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
- 9,835 View
- 443 Download
- 19 Web of Science
- 18 Crossref
- Inflammatory Bowel Diseases
- Quality of life in inflammatory bowel diseases: it is not all about the bowel
- Ronald Keller, Nazar Mazurak, Laura Fantasia, Stefano Fusco, Nisar P Malek, Jan Wehkamp, Paul Enck, Thomas Klag
- Intest Res 2021;19(1):45-52. Published online February 27, 2020
- DOI: https://doi.org/10.5217/ir.2019.00135
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The inflammatory bowel diseases (IBD), ulcerative colitis (UC), and Crohn’s disease (CD) are chronic diseases mostly affecting young patients. As they are diseases accompanying patients for their entire life, and the quality of life (QUOL) interacts with disease activity, improving QUOL should be one of the main goals of therapy. This study aims to identify factors contributing to good or impaired QUOL.
Methods
Questionnaires addressing health-related QUOL and other psychological and social features were positioned on our institutions’ webpage and on the webpage of the largest self-help group for IBD in Germany. Patients were subdivided according to their QUOL score with a cutoff of <60. We used the Short Inflammatory Bowel Disease Questionnaire, the Assessment of the Demand for Additional Psychological Treatment, and the Fear of Progression Questionnaire Short Form.
Results
High numbers of patients in both subgroups showed an impaired QUOL (87.34% in UC, 91.08% in CD). Active extraintestinal manifestations, smoking, high fear of progression and high demand for psychotherapy were associated with reduced QUOL. In addition, polypharmacological interventions did not result in a good QUOL, but ostomies are linked to improved QUOL especially in CD patients.
Conclusions
Scores used in clinical day-to-day-practice mainly focusing on somatic factors do not sufficiently address important aspects concerning QUOL. Most importantly, extraintestinal manifestations show a hitherto underestimated impact on QUOL. -
Citations
Citations to this article as recorded by- Evaluation of the Effect of Probiotic Supplementation on Intestinal Barrier Integrity and Epithelial Damage in Colitis Disease: A Systematic Review
Dilek Sivri, Betül Şeref, Melike Şare Bulut, Makbule Gezmen Karadağ
Nutrition Reviews.2025; 83(7): e1782. CrossRef - Self-perception and adjustment to Crohn's disease in emerging and young adults: The clinical and psychosocial associated factors
Nathalie Touma, Carolina Baeza-Velasco
Pratiques Psychologiques.2025; 31(1): 41. CrossRef - Reducing diagnostic delays of extraintestinal manifestations in inflammatory bowel disease: a comparative study of a multidisciplinary outpatient clinic versus conventional referral specialists
Olga Maria Nardone, Giulio Calabrese, Alessia La Mantia, Guido Daniele Villani, Matteo Megna, Sara Cacciapuoti, Francesca Foglia, Rosario Peluso, Ermelinda D’Alessandro, Mario Ferrante, Anna Testa, Alessia Dalila Guarino, Antonio Rispo, Fabiana Castiglion
Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef - Evolution of Extraintestinal Manifestations in Patients With Ulcerative Colitis Post-Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis: A Single-Center Retrospective Study
Alex Barenboim, Tali Epstein Weiss, Orestis Argyriou, Nathaniel Aviv Cohen, Yehuda Kariv, Meir Zemel, Eran Itzkowitz, Ron Greenberg, Noam Goder, Sara Borok, Kapil Sahnan, Hagit Tulchinsky, Nitsan Maharshak
Inflammatory Bowel Diseases.2025;[Epub] CrossRef - Factors affecting response rates in patient-reported outcome measures in inflammatory bowel disease
Vivica Dharmadasa, Lai Mei Yip Lundström, Niki Khatibi, Jessica Hossain, Kanza El Kadiry, Victoria Byman, Anette Storlåhls, Jan Björk, Francesca Bresso, Marjo Kapraali, Charlotte R. H. Hedin
Scandinavian Journal of Gastroenterology.2025; 60(6): 558. CrossRef - Eosinophilic esophagitis patients report substantial disease burden comparable to more systemic immune-mediated diseases
Eva Theswet, Chiara Brücker, Andrea Kreienbühl, Thomas Greuter, Alain M. Schoepfer, Alex Straumann, Luc Biedermann
BMC Gastroenterology.2025;[Epub] CrossRef - Unravelling the Relationship Between Obesity and Inflammatory Bowel Disease
Jessica Sun, Ella C Brooks, Yashar Houshyar, Susan J Connor, Gokulan Paven, Michael C Grimm, Georgina L Hold
Inflammatory Bowel Diseases.2025;[Epub] CrossRef - Exploring the Clinical Implication of S100A9 in Ulcerative Colitis and Its Progression to Cancer: A Journey from Inflammation to Cancer
Jaehwan Cheon, Sang Hyun Kim, Jaehyung Park, Tae Hoon Kim
International Journal of Molecular Sciences.2025; 26(12): 5693. CrossRef - Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations
Ágnes Eszter Tímár, Andrea Párniczky, Kinga Anna Budai, Márk Viktor Hernádfői, Emese Kasznár, Péter Varga, Péter Hegyi, Szilárd Váncsa, Réka Tóth, Dániel Sándor Veres, Miklós Garami, Katalin Eszter Müller
Journal of Crohn's and Colitis.2024; 18(6): 851. CrossRef - The association between fear of progression and medical coping strategies among people living with HIV: a cross-sectional study
Bing Li, Xiaoli Lin, Suling Chen, Zhe Qian, Houji Wu, Guichan Liao, Hongjie Chen, Zixin Kang, Jie Peng, Guangyu Liang
BMC Public Health.2024;[Epub] CrossRef - Relationship between fear of progression and quality of life in inflammatory bowel disease: Mediating role of health literacy and self‐care
Xin Hu, Liyuan Xu
Journal of Advanced Nursing.2024; 80(10): 4147. CrossRef - Risk Factors of Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study
Jiyoung Yoon, Seung Wook Hong, Kyung-Do Han, Seung-Woo Lee, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Joo Sung Kim, Hyuk Yoon
Gut and Liver.2024; 18(3): 489. CrossRef - Nutritional Profile, Disease Severity, and Quality of Life of Patients with Inflammatory Bowel Disease: A Case–Control Study
Lea N. Sayegh, Firas Haddad, Layane Bou Jaoude, Nicole Fakhoury-Sayegh, Gessica N. H. A. Heraoui, Zainab Nasrallah, Charbel Chidiac, Rashad Nawfal, Fadi F. Francis, Fadi H. Mourad, Jana G. Hashash
Nutrients.2024; 16(12): 1826. CrossRef - Development and Assessment of a Novel Ulcerative Colitis–Specific Quality of Life Questionnaire: A Prospective, Multi-Institutional Study
Jihye Park, Hyun-Soo Zhang, Chung Mo Nam, Joo Sung Kim, Young-Ho Kim, Dong Il Park, Byong Duk Ye, Yoon Tae Jeen, Sehyun Kim, Jae Hee Cheon
Yonsei Medical Journal.2024; 65(11): 636. CrossRef - Comprehensive analysis of psychological symptoms and quality of life in early patients with IBD: a multicenter study from China
Yupei Liu, Jiaming Hu, Shan Tian, Jixiang Zhang, Ping An, Yanrui Wu, Zhongchun Liu, Changqing Jiang, Jie Shi, Kaichun Wu, Weiguo Dong
BMC Psychiatry.2024;[Epub] CrossRef - Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
Gut and Liver.2023; 17(1): 108. CrossRef - Obesity and novel management of inflammatory bowel disease
Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
World Journal of Gastroenterology.2023; 29(12): 1779. CrossRef - A Holistic Perspective on How Photobiomodulation May Influence Fatigue, Pain, and Depression in Inflammatory Bowel Disease: Beyond Molecular Mechanisms
E-Liisa Laakso, Tatjana Ewais
Biomedicines.2023; 11(5): 1497. CrossRef - Psychoemotional disorders of patients with inflammatory bowel diseases: prevalence, pathogenesis and treatment options
Igor G. Bakulin, Venera Sh. Stamboltsyan, Inna A. Oganezova
Russian Family Doctor.2023; 27(2): 23. CrossRef - CE: Nursing Care for Patients After Ostomy Surgery
Heidi H. Cross
AJN, American Journal of Nursing.2023; 123(8): 34. CrossRef - Efficacy and Safety of Infliximab in Intestinal Behçet’s Disease: A Multicenter, Phase 3 Study (BEGIN)
Jae Hee Cheon, Hyun-Soo Kim, Dong Soo Han, Sung Kook Kim, Sung Jae Shin, Joo Sung Kim, Byong Duk Ye, Geun Am Song, YoungJa Lee, Youngdoe Kim, Yoosun Lee, Won Ho Kim
Gut and Liver.2023; 17(5): 777. CrossRef - Validity and reliability of the Indonesian version of the 9-item Inflammatory Bowel Disease Questionnaire (IBDQ-9)
Dekta Filantropi Esa, Hamzah Shatri, Cleopas Martin Rumende, Adityo Susilo, Hasan Maulahela, Achmad Fauzi, Marcellus Simadibrata
Medical Journal of Indonesia.2023; 32(3): 168. CrossRef - Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
Metabolites.2023; 14(1): 2. CrossRef - Apex Score: Predicting Flares in Small-Bowel Crohn’s Disease After Mucosal Healing
Vítor Macedo Silva, Marta Freitas, Pedro Boal Carvalho, Francisca Dias de Castro, Tiago Cúrdia Gonçalves, Bruno Rosa, Maria João Moreira, José Cotter
Digestive Diseases and Sciences.2022; 67(4): 1278. CrossRef - Study on the impact of sexually transmitted infections on Quality of Life, mood and sexual function
Giulia CICCARESE, Francesco DRAGO, Francesco COPELLO, Giorgia BODINI, Alfredo REBORA, Aurora PARODI
Italian Journal of Dermatology and Venereology.2022;[Epub] CrossRef - Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Nagesh Kamat, Sudheer K Vuyyuru, Saurabh Kedia, Pabitra Sahu, Bhaskar Kante, Peeyush Kumar, Mukesh Kumar Ranjan, Mukesh Kumar Singh, Sambuddha Kumar, Vikas Sachdev, Govind Makharia, Vineet Ahuja
Intestinal Research.2022; 20(2): 269. CrossRef - An overview of ozanimod as a therapeutic option for adults with moderate-to-severe active ulcerative colitis
Catherine Rowan, Ryan Ungaro, Saurabh Mehandru, Jean-Frederic Colombel
Expert Opinion on Pharmacotherapy.2022; 23(8): 893. CrossRef - Psychological Effects and Medication Adherence among Korean Patients with Inflammatory Bowel Disease during the Coronavirus Disease 2019 Pandemic: A Single-Center Survey
Ji Eun Ryu, Sung-Goo Kang, Sung Hoon Jung, Shin Hee Lee, Sang-Bum Kang
Journal of Clinical Medicine.2022; 11(11): 3034. CrossRef - The future of telemedicine and wearable technology in IBD
Catherine Rowan, Robert Hirten
Current Opinion in Gastroenterology.2022; 38(4): 373. CrossRef - Corticosteroid, a double-edged sword in inflammatory bowel disease management: possibility of reducing corticosteroid use through physician education
Seulji Kim, Seong-Joon Koh
Intestinal Research.2022; 20(4): 389. CrossRef - The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef - Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative Colitis
Jaeyoung Chun
Gut and Liver.2021; 15(6): 793. CrossRef - Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease
Jose María Huguet, Xavier Cortés, Marta Maia Bosca-Watts, Marian Aguas, Nuria Maroto, Lidia Martí, Cirilo Amorós, Jose María Paredes
World Journal of Clinical Cases.2021; 9(36): 11285. CrossRef - The Reality of Patient-Reported Outcomes of Health-Related Quality of Life in an Italian Cohort of Patients with Inflammatory Bowel Disease: Results from a Cross-Sectional Study
Tiziana Larussa, Danilo Flauti, Ludovico Abenavoli, Luigi Boccuto, Evelina Suraci, Raffaella Marasco, Maria Imeneo, Francesco Luzza
Journal of Clinical Medicine.2020; 9(8): 2416. CrossRef
- Evaluation of the Effect of Probiotic Supplementation on Intestinal Barrier Integrity and Epithelial Damage in Colitis Disease: A Systematic Review
- 10,329 View
- 343 Download
- 33 Web of Science
- 34 Crossref
- Functional bowel disorders
- Psychological profiles of irritable bowel syndrome patients with different phenotypes
- Michel Bouchoucha, Ghislain Devroede, Noëlle Girault-Lidvan, Maria Hejnar, Florence Mary, Robert Benamouzig
- Intest Res 2020;18(4):459-468. Published online October 26, 2020
- DOI: https://doi.org/10.5217/ir.2019.09171
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Abnormal psychological profiles are frequently found in patients with functional gastrointestinal disorders (FGIDs). The present study aimed to evaluate the psychological profiles of FGID patients with irritable bowel syndrome (IBS), and IBS phenotypes.
Methods
In 608 FGID patients, including 235 with IBS, have filled a Rome III questionnaire and the French version of the Minnesota Multiphasic Personality Inventory 2. Data analysis was performed using univariate analysis and multivariate logistic regression.
Results
This study shows that IBS patients have abnormal psychological profiles with more significant symptom exaggeration and decreased test defensiveness than non-IBS patients. They have a significantly higher score for all clinical scales. Logistic regression analysis showed in IBS patients a decrease of body mass index (P= 0.002), and test defensiveness score K (P= 0.001) and an increase of Hypochondriasis (P< 0.001) and Masculinity-Femininity scale (P= 0.018). By comparison with non-IBS patients, IBS-constipation, IBS-diarrhea, and mixed IBS patients have increased Hypochondriasis value and Depression score, mixed IBS patients have higher Psychasthenia score and higher Hypomania score. No item was significantly different in the IBS-unspecified group.
Conclusions
This study shows that IBS patients have different psychological profiles than other FGID patients and that psychological characteristics are associated with IBS phenotypes except for patients with unsubtyped IBS. -
Citations
Citations to this article as recorded by- Psychopathology and the Validity of Gastrointestinal Symptom Reporting as Revealed Through Cluster Analyses of MMPI-2-RF Results
Paris A. Lang, Linda Thomas, Brett A. Lidbury
Digestive Diseases and Sciences.2024; 69(11): 4063. CrossRef - The role of psychological factors in functional gastrointestinal disorders: a systematic review and meta-analysis
Liyanran Yan, Xueli Zhang, Yan Li, Chengjiang Liu, Hua Yang, Chunchun Yang
International Journal of Colorectal Disease.2023;[Epub] CrossRef - An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef - Limited evidence of moderation of the association between gastrointestinal symptoms and prospective healthcare utilisation by quality of life
David T. McNaughton, Anna Andreasson, Brjánn Ljótsson, Alissa P. Beath, Julia M. Hush, Gunnar Ljunggren, Peter T. Schmidt, Nicholas J. Talley, Lars Agréus, Michael P. Jones
Alimentary Pharmacology & Therapeutics.2022; 55(3): 311. CrossRef - Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial
Seung Yong Shin, Sein Park, Jung Min Moon, Kisung Kim, Jeong Wook Kim, Jongsik Chun, Tae Hee Lee, Chang Hwan Choi
Journal of Neurogastroenterology and Motility.2022; 28(4): 642. CrossRef - Psychopathological and neuropsychological disorders associated with chronic primary visceral pain: Systematic review
Alejandro Arévalo-Martínez, Juan Manuel Moreno-Manso, María Elena García-Baamonde, Macarena Blázquez-Alonso, Pilar Cantillo-Cordero
Frontiers in Psychology.2022;[Epub] CrossRef - Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome
Vivek C. Goodoory, Antonina Mikocka-Walus, Yan Yiannakou, Lesley A. Houghton, Christopher J. Black, Alexander C. Ford
American Journal of Gastroenterology.2021; 116(7): 1485. CrossRef
- Psychopathology and the Validity of Gastrointestinal Symptom Reporting as Revealed Through Cluster Analyses of MMPI-2-RF Results
- 18,910 View
- 136 Download
- 8 Web of Science
- 7 Crossref
- Inflammatory bowel diseases
- An assessment of dietary intake, food avoidance and food beliefs in patients with ulcerative colitis of different disease status
- Nor Hamizah Shafiee, Zahara Abdul Manaf, Norfilza M. Mokhtar, Raja Affendi Raja Ali
- Intest Res 2020;18(4):447-458. Published online June 2, 2020
- DOI: https://doi.org/10.5217/ir.2019.00042
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Ulcerative colitis (UC) is a chronic, relapsing and remitting inflammation of the gastrointestinal tract. Little is known about the link between dietary intake, food avoidance, and beliefs among UC patients of different disease severity. Therefore, this study aimed to assess the dietary intake, food avoidance, and beliefs among active and inactive UC patients.
Methods
A cross-sectional study was conducted among UC patients from a tertiary medical center in Kuala Lumpur, Malaysia. Demographic, anthropometric, dietary intake, food avoidance and beliefs were assessed. Disease activity of UC patients was evaluated using the Powell Tuck Index.
Results
UC patients were recruited (64.1% inactive UC and 35.9% active UC). As compared to inactive UC patients, active UC patients were likely to lose weight (75.0% vs. 0%), possess certain food beliefs (95.7% vs. 39.0%), and frequently practiced dietary avoidance (95.7% vs. 43.9%). The dietary intake among inactive UC patients was higher than active UC patients. However, neither of them met the standard nutrients recommendation for protein, calcium, iron, folate, zinc, vitamin D, vitamin B12, and vitamin E.
Conclusions
Active UC patients had poorer dietary intake, were more prone to practicing food avoidance and exhibited certain food beliefs as compared to inactive UC patients. Both macro- and micronutrients intakes were inadequate regardless of patient’s disease status. These findings emphasized the importance for patients to be provided with the nutrition-related knowledge as part of strategies to avoid nutritional inadequacies. -
Citations
Citations to this article as recorded by- Addressing Nutritional Knowledge Gaps in Inflammatory Bowel Disease: A Scoping Review
Eleonora Ribaudi, Simone Amato, Guia Becherucci, Sara Carillo, Carlo Covello, Vincenzina Mora, Maria Chiara Mentella, Franco Scaldaferri, Antonio Gasbarrini, Caterina Fanali, Lucrezia Laterza, Daniele Napolitano
Nutrients.2025; 17(5): 833. CrossRef - Nutritional Deficiencies and Reduced Bone Mineralization in Ulcerative Colitis
Filippo Vernia, Emanuela Ribichini, Giorgia Burrelli Scotti, Giovanni Latella
Journal of Clinical Medicine.2025; 14(9): 3202. CrossRef - Analysis of the Nutritional Value of Diets and Food Choices in Polish Female Ulcerative Colitis Individuals Compared with a Pair-Matched Control Sample
Dominika Głąbska, Dominika Guzek, Gustaw Lech
Nutrients.2023; 15(4): 857. CrossRef - Mobile-based program improves healthy eating of ulcerative colitis patients: A pilot study
Wenjing Tu, Shuxia Yan, Tingting Yin, Sumin Zhang, Wenjing Xu, Ping Zhang, Guihua Xu
DIGITAL HEALTH.2023;[Epub] CrossRef - Self‐reported flares among people living with inflammatory bowel disease are associated with stress and worry but not associated with recent diet changes: The Manitoba Living with IBD Study
Kathy Vagianos, Leigh Anne Shafer, Kelcie Witges, Lesley A. Graff, Laura E. Targownik, Charles N. Bernstein
Journal of Parenteral and Enteral Nutrition.2022; 46(7): 1686. CrossRef - Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intestinal Research.2022; 20(3): 321. CrossRef - Dietary beliefs and information resources of ulcerative colitis patients in clinical remission: A cross-sectional survey in Taiwan
Cheng-Tzu Hsieh, Meng-Tzu Weng, Chien-Chih Tung, Nai-Chia Chen, Hui-Chuen Chen, Kuo-Liong Chien, Shu-Chen Wei
Clinical Nutrition ESPEN.2022; 51: 430. CrossRef - Micronutrient deficiency among patients with ulcerative colitis
Amany Hussien, Sawsan Abd El-Moniem, Ziyad Tawhid, Ahmed Altonbary
The Egyptian Journal of Internal Medicine.2022;[Epub] CrossRef
- Addressing Nutritional Knowledge Gaps in Inflammatory Bowel Disease: A Scoping Review
- 7,536 View
- 154 Download
- 8 Web of Science
- 8 Crossref
- Inflammatory bowel diseases
- Advanced neoplasia detection using chromoendoscopy and white light colonoscopy for surveillance in patients with inflammatory bowel disease
- Kyeong Ok Kim, Michael V. Chiorean
- Intest Res 2020;18(4):438-446. Published online October 26, 2020
- DOI: https://doi.org/10.5217/ir.2019.00090
-
Abstract
PDFPubReaderePub
- Background/Aims
Chromoendoscopy (CE) has been shown to be superior to white light endoscopy (WLE) for neoplasia detection in inflammatory bowel disease (IBD). We aimed to compare the yield of CE and WLE for the detection of overall neoplasia and advanced neoplasia in IBD.
Methods
Patients who underwent surveillance colonoscopy from 1999 to 2017 were identified from our IBD database. CE procedures were compared with their respective WLE controls in a paired comparison, and frequency of all neoplasia, advanced neoplasia, and serrated neoplasia was assessed for both targeted and random biopsies.
Results
A total of 290 procedures performed in 98 individuals were identified with a median follow-up 4 years (median 3 colonoscopies/patient). CE and WLE were performed in 159 and 131 episodes, respectively. CE detected neoplasia in 40.9% of colonoscopies versus 23.7% with WLE (P= 0.002). In addition, CE detected more advanced neoplasia (18.2% vs. 6.1%, P= 0.002) and serrated lesions (14.5% vs. 6.1%, P= 0.022). Significantly fewer samples were obtained per procedure with CE (14.9 ± 9.7 vs. 20.9 ± 11.1, P< 0.001). Cancer was diagnosed in 2 cases.
Conclusions
CE has a higher detection rate than WLE for advanced neoplasia and serrated lesions in patients with IBD under surveillance. Further prospective studies evaluating the impact of CE on decreasing the risk of interval cancer and colectomy in IBD patients are warranted. -
Citations
Citations to this article as recorded by- Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review
Caroline Tanadi, Kevin Tandarto, Maureen Miracle Stella, Kenny Wijaya Sutanto, Mario Steffanus, Riki Tenggara, Muhammad Begawan Bestari
Romanian Journal of Internal Medicine.2024; 62(2): 101. CrossRef - Factors Affecting Adherence to National Colorectal Cancer Screening: A 12-Year Longitudinal Study Using Multi-Institutional Pooled Data in Korea
Dae Sung Kim, Jeeyoung Hong, Kihyun Ryu, Sang Hyuk Lee, Hwanhyi Cho, Jehyeong Yu, Jieun Lee, Jong-Yeup Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef - Feasibility of moxifloxacin and proflavine dual fluorescence imaging for detecting gastrointestinal neoplastic lesions: A prospective study
Kwangwoo Nam, Noseong Park, Seunghun Lee, Suil Jeon, Jungbin Lee, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jeong Hoon Lee, Do Hoon Kim, Ki Hean Kim, Seung‐Jae Myung
Lasers in Surgery and Medicine.2023; 55(4): 378. CrossRef - Colorectal Cancer Surveillance in Patients with Inflammatory Bowel Diseases: Chromoendoscopy or Non-Chromoendoscopy, That Is the Question
Roberto Gabbiadini, Ferdinando D’Amico, Alessandro De Marco, Maria Terrin, Alessandra Zilli, Federica Furfaro, Mariangela Allocca, Gionata Fiorino, Silvio Danese
Journal of Clinical Medicine.2022; 11(3): 509. CrossRef - Efficacy, safety and tolerability of oral sulphate tablet for bowel preparation in patients with inflammatory bowel disease: A multicentre randomized controlled study
Kyeong Ok Kim, Eun Young Kim, Yoo Jin Lee, Hyun Seok Lee, Eun Soo Kim, Yun Jin Chung, Byung Ik Jang, Sung Kook Kim, Chang Heon Yang
Journal of Crohn's and Colitis.2022; 16(11): 1706. CrossRef - Endoscopic activity in inflammatory bowel disease: clinical significance and application in practice
Kyeong Ok Kim
Clinical Endoscopy.2022; 55(4): 480. CrossRef - Image-Enhanced Endoscopy in the Surveillance of Colitis-Associated Neoplasia
Olga Maria Nardone, Marietta Iacucci
Gastrointestinal Endoscopy Clinics of North America.2022; 32(4): 845. CrossRef - Active Assessment of Inflammatory Bowel Disease
金良 肖
Advances in Clinical Medicine.2022; 12(12): 11023. CrossRef - Chromoendoskopie – Alles, was man wissen muss
Lisa Amsberg, Ulrike Schempf, Dörte Wichmann
Endo-Praxis.2022; 38(04): 169. CrossRef - Underutilization of societal guidelines: occasional or widespread?
Richard Kozarek
Endoscopy International Open.2021; 09(07): E986. CrossRef
- Colorectal cancer screening guidelines for average-risk and high-risk individuals: A systematic review
- 5,928 View
- 101 Download
- 7 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Prevalence and patient awareness of inflammatory bowel disease in Kazakhstan: a cross-sectional study
- Jamilya Kaibullayeva, Aliya Ualiyeva, Ainash Oshibayeva, Anar Dushpanova, John K. Marshall
- Intest Res 2020;18(4):430-437. Published online September 29, 2020
- DOI: https://doi.org/10.5217/ir.2019.00099
-
Abstract
PDFPubReaderePub
- Background/Aims
There has been a paucity of published data on the epidemiology of inflammatory bowel disease (IBD) in Central Asia and Kazakhstan. Therefore, we aimed to study IBD prevalence and patient awareness among adults in Kazakhstan.
Methods
The cross-sectional study was carried out among subjects of both sexes aged 18 years and older using IBD Alert Questionnaire (CalproQuest), single fecal calprotectin test, and endoscopy with biopsy to verify IBD from January to December 2017, across regions of Kazakhstan. All participants were included in the study after providing informed consent.
Results
Out of 115,556 subjects, there were 128 confirmed IBD cases, in which 36 Crohn’s disease (CD) and 92 ulcerative colitis (UC) cases identified. The age and sex-adjusted IBD prevalence were 113.9 (95% confidence interval [CI], 69.0–158.9) per 100,000 population. The age- and sex-adjusted prevalence for UC were 84.4 (95% CI, 44.8–123.9) and for CD were 29.5 (95% CI, 8.2–50.9) per 100,000 population.
Conclusions
This is the first report on the prevalence of IBD with a verified diagnosis in the Central Asia and could be used to better plan and allocate healthcare resources for IBD management program. -
Citations
Citations to this article as recorded by- A review investigating delays in Crohn's disease diagnosis
Christophe Souaid, Eddy Fares, Paul Primard, Gilles Macaigne, Weam El Hajj, Stephane Nahon
Clinics and Research in Hepatology and Gastroenterology.2025; 49(1): 102500. CrossRef - Awareness of inflammatory bowel disease among the general population of Al-Baha region, Saudi Arabia
Turki Alkully, Sarah Taishan, Wafaa Taishan, Lara Alsakka, Njood Alghamdi, Nouf Alghamdi, Mohammed Alghamdi
Journal of Medicine and Life.2024; 17(2): 164. CrossRef - Capsule endoscopy in Kazakhstan: a multicenter clinical experience
Sang Jun Sohn, Kanat Batyrbekov, Ainura Galiakbarova, Laura Yerdaliyeva, Jamilya Kaibullayeva, Jeongwoo Ju, Haejin Lee, Yeoun Joo Lee
Kosin Medical Journal.2024; 39(3): 179. CrossRef - Systematic review with meta‐analysis: Time to diagnosis and the impact of delayed diagnosis on clinical outcomes in inflammatory bowel disease
Nishani Jayasooriya, Samantha Baillie, Jonathan Blackwell, Alex Bottle, Irene Petersen, Hanna Creese, Sonia Saxena, Richard C. Pollok
Alimentary Pharmacology & Therapeutics.2023; 57(6): 635. CrossRef - Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea
Kwangwoo Nam, Jae Yong Lee, Yousun Ko, Kyung Won Kim, Ho-Su Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byoun, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Digestive Diseases and Sciences.2023; 68(6): 2165. CrossRef - Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, Jungbok Lee, Sang Hyoung Park, Suk-Kyun Yang, Hyuk Yoon, You Sun Kim, Chang Hwan Choi, Byong Duk Ye
Intestinal Research.2023; 21(1): 137. CrossRef - Obesity and novel management of inflammatory bowel disease
Jee Hyun Kim, Chang-Myung Oh, Jun Hwan Yoo
World Journal of Gastroenterology.2023; 29(12): 1779. CrossRef - Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef - Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990–2019: A Comprehensive Analysis Based on the Global Burden of Disease Study
Xuejie Chen, Xin Xiang, Weitong Xia, Xindi Li, Sidan Wang, Shuyu Ye, Li Tian, Lian Zhao, Feiyan Ai, Zhaohua Shen, Kai Nie, Minzi Deng, Xiaoyan Wang
Journal of Epidemiology and Global Health.2023; 13(4): 725. CrossRef - Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy
Kyunghwan Oh, Eun Hye Oh, Soo Min Noh, Seong Ho Park, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Clinical and Translational Gastroenterology.2022; 13(1): e00442. CrossRef - Changes in the Long-term Prognosis of Crohn’s Disease between 1986 and 2015: The Population-Based Songpa-Kangdong Inflammatory Bowel Disease Cohort Study
Byong Duk Ye, Sung Noh Hong, Seung In Seo, Ye-Jee Kim, Jae Myung Cha, Kyoung Hoon Rhee, Hyuk Yoon, Young-Ho Kim, Kyung Ho Kim, Sun Yong Park, Seung Kyu Jeong, Ji Hyun Lee, Hyunju Park, Joo Sung Kim, Jong Pil Im, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim,
Gut and Liver.2022; 16(2): 216. CrossRef - Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intestinal Research.2022; 20(2): 159. CrossRef - Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
Sun-Ho Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye
Intestinal Research.2022; 20(2): 203. CrossRef - Clinical Course of Hepatitis B Viral Infection in Patients Undergoing Anti-Tumor Necrosis Factor α Therapy for Inflammatory Bowel Disease
Ji Min Lee, Shu-Chen Wei, Kang-Moon Lee, Byong Duk Ye, Ren Mao, Hyun-Soo Kim, Soo Jung Park, Sang Hyoung Park, Eun Hye Oh, Jong Pil Im, Byung Ik Jang, Dae Bum Kim, Ken Takeuchi
Gut and Liver.2022; 16(3): 396. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Medication Adherence in Korean Patients with Inflammatory Bowel
Disease and Its Associated Factors
Kyunghwan Oh, Eun Ja Kwon, Jeong Hye Kim, Kyuwon Kim, Jae Yong Lee, Hee Seung Hong, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Jeong Yun Park, Sang Hyoung Park
The Ewha Medical Journal.2022; 45(2): 35. CrossRef - Evaluation of nutritional status using bioelectrical impedance analysis in patients with inflammatory bowel disease
Seung Hyuk Kim, You Sun Kim, Si Hyeong Lee, Hyun Mi Lee, Won Eui Yoon, Seo Hyun Kim, Hee Jun Myung, Jeong Seop Moon
Intestinal Research.2022; 20(3): 321. CrossRef - Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis
Kyuwon Kim, Hee Seung Hong, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Byong Duk Ye, Sang Hyoung Park
The Korean Journal of Internal Medicine.2022; 37(6): 1140. CrossRef - Inflammatory bowel disease in Korea: epidemiology and pathophysiology
Jung Won Lee, Chang Soo Eun
The Korean Journal of Internal Medicine.2022; 37(5): 885. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - What Are the Different Phenotypes of Inflammatory Bowel Disease in Asia?
Su Bee Park, Jin Young Yoon, Jae Myung Cha
Gut and Liver.2022; 16(5): 676. CrossRef - Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intestinal Research.2022; 20(4): 418. CrossRef - Clinical Features and Long-term Prognosis of Crohn’s Disease in Korea: Results from the Prospective CONNECT Study
Seung Wook Hong, Byong Duk Ye, Jae Hee Cheon, Ji Hyun Lee, Ja Seol Koo, Byung Ik Jang, Kang-Moon Lee, You Sun Kim, Tae Oh Kim, Jong Pil Im, Geun Am Song, Sung-Ae Jung, Hyun Soo Kim, Dong Il Park, Hyun-Soo Kim, Kyu Chan Huh, Young-Ho Kim, Jae Myung Cha, Ge
Gut and Liver.2022; 16(6): 907. CrossRef - The epidemiology of inflammatory bowel disease in Asia and Asian immigrants to Western countries
Satimai Aniwan, Priscila Santiago, Edward V. Loftus, Sang Hyoung Park
United European Gastroenterology Journal.2022; 10(10): 1063. CrossRef - Public awareness toward inflammatory bowel disease in Saudi Arabia
Siraj Eid, Saeed Mohammad, Sulafa Noorelahi, Ali Asiri, Abdullah Taha, Ghallah Najee, Abdulkarim Aldukhail, Taif Alenezi, Rajis Aldosari
International Journal of Medicine in Developing Countries.2021; : 929. CrossRef - The Clinical Features of Inflammatory Bowel Disease in Patients with Obesity
Seong Kyun Kim, Ho-Su Lee, Beom-Jun Kim, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park, Masanao Nakamura
Canadian Journal of Gastroenterology and Hepatology.2021; 2021: 1. CrossRef - Optimal Cutoff Level of Fecal Calprotectin for Detecting Small Bowel Inflammation in Crohn's Disease
Eun Soo Kim
Gut and Liver.2021; 15(5): 637. CrossRef - Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn’s disease: a retrospective study
Hee Seung Hong, Kyuwon Kim, Kyunghwan Oh, Jae Yong Lee, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef - Real world practice of medical treatment for moderate and severe inflammatory bowel diseases in Russian Federation, Republic of Belarus and Republic of Kazakhstan: intermediate results of the INTENT study
O. V. Knyazev, E. A. Belousova, D. I. Abdulganieva, I. V. Gubonina, J. A. Kaibullayeva, Yu. Kh. Marakhouski, E. Yu. Chashkova, M. V. Shapina, O. B. Shchukina, B. B. Gegenava, N. S. Oliferuk
Almanac of Clinical Medicine.2021; 49(7): 443. CrossRef - The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia
Seung Wook Hong, Byong Duk Ye
Intestinal Research.2020; 18(4): 345. CrossRef - Pediatric Ulcerative Colitis in Kazakhstan: First Case Series from Central Asia and Current Clinical Management
Dimitri Poddighe, Aigerim Telman, Ernas Tuleutayev, Aigul Ibrayeva
Gastroenterology Insights.2020; 11(2): 27. CrossRef
- A review investigating delays in Crohn's disease diagnosis
- 6,763 View
- 133 Download
- 31 Web of Science
- 33 Crossref
- Inflammatory bowel diseases
- Pathophysiological role of Atg5 in human ulcerative colitis
- Razieh Ardali, Nasrin Kazemipour, Saeed Nazifi, Kamran Bagheri Lankarani, Iman Razeghian Jahromi, Masood Sepehrimanesh
- Intest Res 2020;18(4):421-429. Published online May 8, 2020
- DOI: https://doi.org/10.5217/ir.2019.00120
-
Abstract
PDFPubReaderePub
- Background/Aims
Ulcerative colitis (UC), along with Crohn’s disease, is one of the main types of inflammatory bowel disease (IBD). On the other hand, deregulated autophagy is involved in many chronic diseases, including IBD. In this study, we aimed to investigate the role of Atg5 and microRNA-181a (miR-181a) in the pathophysiology of UC.
Methods
Colon biopsy, stool, and blood samples of 6 men and 9 women were confirmed for UC. Also, 13 men and 17 women were selected as healthy control (HC). Enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry were used to measure the Atg-5 content of the colon biopsies. Besides, the serum and stool levels of Atg5 were measured using ELISA. Moreover, the total RNA of blood cells was extracted and evaluated for the expression of miR-181a.
Results
We found 1.2 ng/mL versus 0.46 ng/mL, 0.34 ng/mL versus 0.24 ng/mL, and 0.082 ng/mL versus 0.062 ng/mL of Atg5 in stool, intestinal tissue, and serum of UC and HCs, respectively. There was no significant difference in the expression of miR-181a in the blood samples of UC and HCs. Immunohistochemistry showed high positivity without any significant difference between the 2 groups in the quantitative analysis.
Conclusions
The significant difference observed between the stool Atg5 content of the HCs and UC patients may provide new insight into using this protein as a diagnostic biomarker, however, considering the small size of our studied population further studies are needed. -
Citations
Citations to this article as recorded by- Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date
Alessandro Giammona, Bruno Giovanni Galuzzi, Elena Imperia, Clarissa Gervasoni, Sofia Remedia, Laura Restaneo, Martina Nespoli, Laura De Gara, Flaminia Tani, Michele Cicala, Michele Pier Luca Guarino, Danilo Porro, Antonio Cerasa, Alessia Lo Dico, Annamar
International Journal of Molecular Sciences.2025; 26(1): 413. CrossRef - Circular RNAs in inflammatory bowel disease: a review of mechanisms, biomarkers and therapeutic potential
Le Yang, Huahui Li, Min Tang, Lingnan He, Lijun Yang
Frontiers in Immunology.2025;[Epub] CrossRef - Pharmacological induction of autophagy reduces inflammation in macrophages by degrading immunoproteasome subunits
Jiao Zhou, Chunxia Li, Meng Lu, Gaoyue Jiang, Shanze Chen, Huihui Li, Kefeng Lu, Hans-Uwe Simon
PLOS Biology.2024; 22(3): e3002537. CrossRef - Autophagy: A potential target for natural products in the treatment of ulcerative colitis
Wei Zhang, Menglong Zou, Jia Fu, Yin Xu, Ying Zhu
Biomedicine & Pharmacotherapy.2024; 176: 116891. CrossRef - Deficiency of Autophagy-Related Gene 5 in Keratinocytes Leads to Aggravation of Epidermal Damage in 2,4-Dinitrochlorobenzene-Induced Allergic Contact Dermatitis
Yi-Qun Zhang, Ta Xiao, Chang-Jun Song, Yang-Ying Ke, Xiang Gao, Min Li, Heng Gu, Xu Chen
International Journal of Dermatology and Venereology.2023; 6(4): 214. CrossRef - Circular RNA HECTD1 Mitigates Ulcerative Colitis by Promoting Enterocyte Autophagy Via miR-182-5p/HuR Axis
Yan Xu, Yuxi Tian, Fujun Li, Ying Wang, Junwen Yang, Hui Gong, Xiaoping Wan, Miao Ouyang
Inflammatory Bowel Diseases.2022; 28(2): 273. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs
Soo-Young Na, You Sun Kim
The Korean Journal of Internal Medicine.2022; 37(5): 906. CrossRef - A study on the potential role of autophagy‐related protein 10 as a biomarker for ulcerative colitis
Fatemeh Abbasi Teshnizi, Nasrin Kazemipour, Saeed Nazifi, Kamran Bagheri Lankarani, Masood Sepehrimanesh, Iman Razeghian Jahromi
Physiological Reports.2021;[Epub] CrossRef - Regulation of Endoplasmic Reticulum Stress-Autophagy: A Potential Therapeutic Target for Ulcerative Colitis
Dan Qiao, Ziwei Zhang, Yali Zhang, Qian Chen, Yujun Chen, Yingjue Tang, Xiong Sun, Zhipeng Tang, Yancheng Dai
Frontiers in Pharmacology.2021;[Epub] CrossRef
- Chronic Gastrointestinal Disorders and miRNA-Associated Disease: An Up-to-Date
- 6,334 View
- 134 Download
- 9 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Phenotypic characteristics of pediatric inflammatory bowel disease in Japan: results from a multicenter registry
- Katsuhiro Arai, Reiko Kunisaki, Fumihiko Kakuta, Shin-ichiro Hagiwara, Takatsugu Murakoshi, Tadahiro Yanagi, Toshiaki Shimizu, Sawako Kato, Takashi Ishige, Tomoki Aomatsu, Mikihiro Inoue, Takeshi Saito, Itaru Iwama, Hisashi Kawashima, Hideki Kumagai, Hitoshi Tajiri, Naomi Iwata, Takahiro Mochizuki, Atsuko Noguchi, Toshihiko Kashiwabara, Hirotaka Shimizu, Yasuo Suzuki, Yuri Hirano, Takeo Fujiwara
- Intest Res 2020;18(4):412-420. Published online August 18, 2020
- DOI: https://doi.org/10.5217/ir.2019.00130
-
Abstract
PDFPubReaderePub
- Background/Aims
There are few published registry studies from Asia on pediatric inflammatory bowel disease (IBD). Registry network data enable comparisons among ethnic groups. This study examined the characteristics of IBD in Japanese children and compared them with those in European children.
Methods
This was a cross-sectional multicenter registry study of newly diagnosed Japanese pediatric IBD patients. The Paris classification was used to categorize IBD features, and results were compared with published EUROKIDS data.
Results
A total of 265 pediatric IBD patients were initially registered, with 22 later excluded for having incomplete demographic data. For the analysis, 91 Crohn’s disease (CD), 146 ulcerative colitis (UC), and 6 IBD-unclassified cases were eligible. For age at diagnosis, 20.9% of CD, 21.9% of UC, and 83.3% of IBD-unclassified cases were diagnosed before age 10 years. For CD location, 18.7%, 13.2%, 64.8%, 47.3%, and 20.9% were classified as involving L1 (ileocecum), L2 (colon), L3 (ileocolon), L4a (esophagus/stomach/duodenum), and L4b (jejunum/proximal ileum), respectively. For UC extent, 76% were classified as E4 (pancolitis). For CD behavior, B1 (non-stricturing/non-penetrating), B2 (stricturing), B3 (penetrating), and B2B3 were seen in 83.5%, 11.0%, 3.3%, and 2.2%, respectively. A comparison between Japanese and European children showed less L2 involvement (13.2% vs. 27.3%, P< 0.01) but more L4a (47.3% vs. 29.6%, P< 0.01) and L3 (64.8% vs. 52.7%, P< 0.05) involvement in Japanese CD children. Pediatric perianal CD was more prevalent in Japanese children (34.1% vs. 9.7%, P< 0.01).
Conclusions
Upper gastrointestinal and perianal CD lesions are more common in Japanese children than in European children. -
Citations
Citations to this article as recorded by- Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure
Yoko Yamamoto, Ichiro Takeuchi, Hirotaka Shimizu, Hiroki Fujikawa, Masanori Toda, Eri Miyata, Hiroaki To, Satoru Nagata, Katsuhiro Arai
Journal of Gastroenterology and Hepatology.2025; 40(1): 123. CrossRef - Outcome of pediatric inflammatory bowel disease in Asian children: a multinational 1-year follow-up study
Pornthep Tanpowpong, Suporn Treepongkaruna, James Guoxian Huang, Kee Seang Chew, Karen Sophia Calixto Mercado, Almida Reodica, Shaman Rajindrajith, Wathsala Hathagoda, Yoko Kin Yoke Wong, Way Seah Lee, Marion Margaret Aw
Clinical and Experimental Pediatrics.2025; 68(3): 247. CrossRef - Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore–Malaysia Study From the Asian PIBD Registry Network
James Guoxian Huang, Kee Seang Chew, Veena Logarajah, Way Seah Lee, Marion Margaret Aw
Journal of Gastroenterology and Hepatology.2025;[Epub] CrossRef - Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry‐based cohort study
Ryusuke Nambu, Takahiro Kudo, Nao Tachibana, Hirotaka Shimizu, Tatsuki Mizuochi, Sawako Kato, Mikihiro Inoue, Hideki Kumagai, Takashi Ishige, Reiko Kunisaki, Atsuko Noguchi, Toshifumi Yodoshi, Shin‐Ichiro Hagiwara, Shigeo Nishimata, Fumihiko Kakuta, Takes
Journal of Gastroenterology and Hepatology.2024; 39(2): 312. CrossRef - Prevalence of Inflammatory Bowel Disease Unclassified, as Estimated Using the Revised Porto Criteria, among Korean Pediatric Patients with Inflammatory Bowel Disease
Sung Hee Lee, Minsoo Shin, Seo Hee Kim, Seong Pyo Kim, Hyung-Jin Yoon, Yangsoon Park, Jaemoon Koh, Seak Hee Oh, Jae Sung Ko, Jin Soo Moon, Kyung Mo Kim
Pediatric Gastroenterology, Hepatology & Nutrition.2024; 27(4): 206. CrossRef - Clinical Efficacy and Future Application of Indigo Naturalis in the Treatment of Ulcerative colitis
Dianzhen Wu, Qi Huang, Yingbi Xu, Ruiyi Cao, Ming Yang, Jin Xie, Dingkun Zhang
Journal of Ethnopharmacology.2024; : 118782. CrossRef - Validation of the simplified PIBD‐classes criteria: A single‐center retrospective study
Yoshikazu Miura, Shin‐ichiro Hagiwara, Keinosuke Hizuka, Ryutaro Saura, Ayaha Hata, Takatoshi Maeyama, Yuri Etani
Pediatrics International.2024;[Epub] CrossRef - Comparison of Clinical Outcomes in Pediatric Patients with Ileocolonic Crohn Disease Treated with Infliximab Versus Adalimumab
Eliana Fanous, Tal Marshanski, Noa Tal, Manar Matar, Yael Weintraub, Raanan Shamir, Dror S. Shouval
Journal of Pediatric Gastroenterology and Nutrition.2023; 77(3): 358. CrossRef - Caracterización clínica y terapéutica de una cohorte multicéntrica de pacientes con enfermedad inflamatoria intestinal en Colombia
Viviana Parra-Izquierdo, Cristian Flórez Sarmiento, Juan Sebastián Frías-Ordoñez, Melquicedec Vargas, Joshua Kock, Natalia Lozano Escobar, Juan Ricardo Márquez
Gastroenterología y Hepatología.2023; 46(8): 585. CrossRef - Potential of Gut Microbe-Derived Extracellular Vesicles to Differentiate Inflammatory Bowel Disease Patients from Healthy Controls
Min Heo, Young Soo Park, Hyuk Yoon, Nam-Eun Kim, Kangjin Kim, Cheol Min Shin, Nayoung Kim, Dong Ho Lee
Gut and Liver.2023; 17(1): 108. CrossRef - Medical management of pediatric inflammatory bowel disease in the Asia‐Pacific region: A position paper by the Asian Pan‐Pacific Society for Pediatric Gastroenterology, Hepatology, and Nutrition (APPSPGHAN) PIBD Working Group
Way Seah Lee, Katsuhiro Arai, George Alex, Suporn Treepongkaruna, Kyung Mo Kim, Chee Liang Choong, Karen S. C. Mercado, Andy Darma, Anshu Srivastava, Marion M. Aw
Journal of Gastroenterology and Hepatology.2023; 38(4): 523. CrossRef - Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study
Ryusuke Nambu, Katsuhiro Arai, Takahiro Kudo, Takatsugu Murakoshi, Reiko Kunisaki, Tatsuki Mizuochi, Sawako Kato, Hideki Kumagai, Mikihiro Inoue, Takashi Ishige, Takeshi Saito, Atsuko Noguchi, Toshifumi Yodoshi, Shin-Ichiro Hagiwara, Naomi Iwata, Shigeo N
Journal of Gastroenterology.2023; 58(5): 472. CrossRef - Mucosal immune systems of pediatric inflammatory bowel disease: A review
Takahiro Kudo, Toshiaki Shimizu
Pediatrics International.2023;[Epub] CrossRef - Clinical and therapeutic characterisation of a multicentre cohort of patients with inflammatory bowel disease in Colombia
Viviana Parra-Izquierdo, Cristian Flórez Sarmiento, Juan Sebastián Frías-Ordoñez, Melquicedec Vargas, Joshua Kock, Natalia Lozano Escobar, Juan Ricardo Márquez
Gastroenterología y Hepatología (English Edition).2023; 46(8): 585. CrossRef - Clinical characteristics and nursing diagnoses of pediatric patients hospitalized with inflammatory bowel disease: a single-center retrospective study in South Korea
Sung-Yoon Jo, Kyung-Sook Bang
Child Health Nursing Research.2023; 29(3): 218. CrossRef - Clinical Features and Long-Term Outcomes of Paediatric-Onset Inflammatory Bowel Disease in a Population-Based Cohort in the Songpa-Kangdong District of Seoul, Korea
Sang Hyoung Park, Jong Pil Im, Hyunju Park, Seung Kyu Jeong, Ji Hyun Lee, Kyoung Hoon Rhee, Young-Ho Kim, Sung Noh Hong, Kyung Ho Kim, Seung In Seo, Jae Myung Cha, Sun Yong Park, Joo Sung Kim, Hyuk Yoon, Sung Hoon Kim, Jisun Jang, Jeong Hwan Kim, Seong O
Journal of Crohn's and Colitis.2022; 16(2): 207. CrossRef - Long-term Disease Course of Crohn’s Disease: Changes in Disease Location, Phenotype, Activities, and Predictive Factors
Choong Wui Cho, Myung-Won You, Chi Hyuk Oh, Chang Kyun Lee, Sung Kyoung Moon
Gut and Liver.2022; 16(2): 157. CrossRef - Symptom Improvement of ulceRative colitis after an Induction dose of UStekinumab in Japanese clinical practice (SIRIUS), measured using patient-reported outcomes: a prospective observational study
Katsuyoshi Matsuoka, Katsumasa Nagano, Shinya Nagasaki, Yoko Murata, Tadakazu Hisamatsu
BMJ Open.2022; 12(5): e060081. CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Phenotypic Pattern of Early Versus Later‐Onset Pediatric Inflammatory Bowel Disease in a Eurasian Country
Bilge S. Akkelle, Deniz Ertem, Burcu Volkan, Engin Tutar
Journal of Pediatric Gastroenterology and Nutrition.2022;[Epub] CrossRef - Clinical features of very early-onset inflammatory bowel disease in Japan: a retrospective single-center study
Masaaki Usami, Ichiro Takeuchi, Reiko Kyodo, Yuri Hirano, Kosuke Kashiwagi, Hiroki Fujikawa, Hirotaka Shimizu, Toshinao Kawai, Katsuhiro Arai
Intestinal Research.2022; 20(4): 475. CrossRef - SYSTEMATIC REVIEW AND META - ANALYSIS OF THE FREQUENCY AND RE-CLASSIFICATION TRENDS OF PEDIATRIC INFLAMMATORY BOWEL DISEASE - UNCLASSIFIED
Rishi BOLIA, Akhil Dhanesh GOEL
Arquivos de Gastroenterologia.2022; 59(4): 531. CrossRef - Comparison between Pediatric Crohn’s Disease and Ulcerative Colitis at Diagnosis in Korea: Results from a Multicenter, Registry-Based, Inception Cohort Study
Sowon Park, Ben Kang, Seung Kim, Sujin Choi, Hyo Rim Suh, Eun Sil Kim, Ji Hyung Park, Mi Jin Kim, Yon Ho Choe, Yeoun Joo Lee, Jae Hong Park, Eell Ryoo, Hong Koh, Byung-Ho Choe
Gut and Liver.2022; 16(6): 921. CrossRef - Epidemiology and diagnosis of inflammatory bowel diseases
Kang-Moon Lee
Journal of the Korean Medical Association.2021; 64(9): 579. CrossRef - Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, Upender Shava, Girish Ganesh, D. Nageshwar Reddy
Intestinal Research.2021; 19(4): 398. CrossRef - Incidentally Detected Asymptomatic Perianal Abscess in an Adolescent during Crohn's Disease Diagnosis: Is Routine Pelvic Imaging Required in Korean Pediatric Patients at Diagnosis?
Soo Hyun Um, Sang Woo Lee, Ki Hwan Song, So Mi Lee, Byung-Ho Choe, Yoo Min Lee, Ben Kang
Pediatric Gastroenterology, Hepatology & Nutrition.2021; 24(6): 564. CrossRef
- Long‐term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti‐tumor necrosis factor failure
- 7,369 View
- 215 Download
- 24 Web of Science
- 26 Crossref
- Inflammatory bowel diseases
- A glycolipid adjuvant, 7DW8-5, provides a protective effect against colonic inflammation in mice by the recruitment of CD1d-restricted natural killer T cells
- Chansu Lee, Sung Noh Hong, Young-Ho Kim
- Intest Res 2020;18(4):402-411. Published online April 8, 2020
- DOI: https://doi.org/10.5217/ir.2019.00132
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The modulation of CD1d-restricted natural killer T (NKT) cells by glycolipids has been considered as a potential therapy against immunologic diseases, including inflammatory bowel disease. A recently identified a glycolipid analog, 7DW8-5, which is derived from α-galactosylceramide (α-GalCer), is as much as 100-fold more active at stimulating both human and mice NKT cells when compared to α-GalCer. We explored the effects of 7DW8-5 in mouse models of acute and chronic colitis.
Methods
We investigated the effects of 7DW8-5 on intestinal inflammation by assessing the effects of 7dW8-5 on a murine dextran sulfate sodium (DSS)-induced acute colitis model and a chronic colitis-associated tumor model.
Results
The acute DSS-induced colitis model showed a dose-dependent response to 7DW8-5, as mice administered 7DW8-5 showed a significant improvement in DSS-induced colitis based on their disease activity index, histologic analysis, and serum C-reactive protein levels, when compared to mice administered vehicle alone. However, DSS-induced colitis in CD1d-KO mice showed no response to 7DW8-5. A fluorescence-activating cell sorting analysis revealed an increase in NKT cells in colonic tissues of 7DW8-5-treated mice. RNA-seq and real-time quantitative polymerase chain reaction showed a significant increase in the expression of interleukin (IL)-4, IL-13, and interferon-gamma in 7DW8-5-treated mice. In addition, 7DW8-5 treatment reduced colitis-associated tumor development in an azoxymethane/DSS mouse model.
Conclusions
7DW8-5 activates NKT cells through CD1d and provides a protective effect against intestinal inflammation in mice. Therefore, 7DW8-5 may be a promising therapeutic agent for treatment of inflammatory bowel disease. -
Citations
Citations to this article as recorded by- Role of CD1d and iNKT cells in regulating intestinal inflammation
Sung Won Lee, Hyun Jung Park, Luc Van Kaer, Seokmann Hong
Frontiers in Immunology.2024;[Epub] CrossRef - An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
Moriya Tsuji, Manoj S. Nair, Kazuya Masuda, Candace Castagna, Zhenlu Chong, Tamarand L. Darling, Kuljeet Seehra, Youngmin Hwang, Ágata Lopes Ribeiro, Geovane Marques Ferreira, Laura Corredor, Jordana Grazziela Alves Coelho-dos-Reis, Yukiko Tsuji, Munemasa
Nature Communications.2023;[Epub] CrossRef - Inhibition of the Occurrence and Development of Inflammation-Related Colorectal Cancer by Fucoidan Extracted from Sargassum fusiforme
Xiang Li, Shijun Xin, Xiaoqun Zheng, Liqin Lou, Shiqing Ye, Shengkai Li, Qilong Wu, Qingyong Ding, Ling Ji, Chunrong Nan, Yongliang Lou
Journal of Agricultural and Food Chemistry.2022; 70(30): 9463. CrossRef - Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice
Felicia N. Watson, Caroline J. Duncombe, Anya C. Kalata, Ethan Conrad, Sumana Chakravarty, B. Kim Lee Sim, Stephen L. Hoffman, Moriya Tsuji, Melanie J. Shears, Sean C. Murphy
Biomolecules.2022; 13(1): 8. CrossRef
- Role of CD1d and iNKT cells in regulating intestinal inflammation
- 6,791 View
- 155 Download
- 4 Web of Science
- 4 Crossref
- Miscellaneous
- Melatonin in the colon modulates intestinal microbiota in response to stress and sleep deprivation
- Young Sook Park, Soo Hyung Kim, Jong Won Park, Younglim Kho, Pu Rum Seok, Jae-Ho Shin, Yoon Ji Choi, Jin-Hyun Jun, Hee Chan Jung, Eun Kyung Kim
- Intest Res 2020;18(3):325-336. Published online June 23, 2020
- DOI: https://doi.org/10.5217/ir.2019.00093
-
Abstract
PDFPubReaderePub
- Background/Aims
Stress is closely related to the deterioration of digestive disease. Melatonin has potent anti-inflammatory properties. The objective of this study was to determine the effect of water stress (WS) and sleep deprivation (SD) on intestinal microbiota and roles of melatonin in stressful condition.
Methods
We used C57BL/6 mice and specially designed water bath for stress and SD for 10 days. We measured melatonin concentrations in serum, feces, and colon tissues by high-performance liquid chromatography. Genomic DNA was extracted from feces and amplified using primers targeting V3 to V4 regions of bacterial 16S ribosomal RNA genes.
Results
Compared to the control, melatonin concentration was lower in the WS and SD. Fecal concentration was 0.132 pg/mL in control, 0.062 pg/mL in WS, and 0.068 pg/mL in SD. In colon tissue, it was 0.45 pg/mL in control, 0.007 pg/mL in WS, and 0.03 pg/mL in SD. After melatonin treatment, melatonin concentrations in feces and colon tissue were recovered to the level of control. Metagenomic analysis of microbiota showed abundance in colitogenic microbiota in WS and SD. Melatonin injection attenuated this harmful effect. WS and SD showed decreased Lactobacillales and increased Erysipelotrichales and Enterobacteriales. Melatonin treatment increased Akkermansia muciniphila and Lactobacillus and decreased Bacteroides massiliensis and Erysipelotrichaceae.
Conclusions
This study showed that stress and SD could affect intestinal dysbiosis and increase colitogenic microbiota, which could contribute to the aggravating digestive disease. Melatonin concentrations in feces and colon tissue decreased under WS and SD. Melatonin treatment brought recovery of melatonin concentration in colon tissue and modulating dysbiosis of intestinal microbiota. -
Citations
Citations to this article as recorded by- Advances in molecular mechanisms and therapeutic strategies for central nervous system diseases based on gut microbiota imbalance
Wei Tao, Yanren Zhang, Bingbin Wang, Saiqun Nie, Li Fang, Jian Xiao, Yanqing Wu
Journal of Advanced Research.2025; 69: 261. CrossRef - Sleep deprivation-induced shifts in gut microbiota: Implications for neurological disorders
Nitu L. Wankhede, Mayur B. Kale, Ashishkumar Kyada, Rekha M M, Kamlesh Chaudhary, K.Satyam Naidu, Sandip Rahangdale, Prajwali V. Shende, Brijesh G. Taksande, Mohammad Khalid, Monica Gulati, Milind J. Umekar, Mohammad Fareed, Spandana Rajendra Kopalli, Sus
Neuroscience.2025; 565: 99. CrossRef - Chronic Dexamethasone Disturbs the Circadian Rhythm of Melatonin and Clock Genes in Goats
Liuping Cai, Qu Chen, Canfeng Hua, Liqiong Niu, Qijun Kong, Lei Wu, Yingdong Ni
Animals.2025; 15(1): 115. CrossRef - The use of melatonin in the treatment of irritable bowel syndrome: a systematic review of randomized placebo-controlled clinical trials
D. S. Mironov, I. A. Spirin, T. N. Trubeckaya, N. S. Shitova, V. A. Postoev
Experimental and Clinical Gastroenterology.2024; (9): 168. CrossRef - Mechanism of Action of Melatonin as a Potential Adjuvant Therapy in Inflammatory Bowel Disease and Colorectal Cancer
Abdo Jurjus, Jad El Masri, Maya Ghazi, Lemir Majed El Ayoubi, Lara Soueid, Alice Gerges Geagea, Rosalyn Jurjus
Nutrients.2024; 16(8): 1236. CrossRef - Association between sleep disorders and constipation Risk: A systematic review and Meta-Analysis
Minhui Tian, Yongfu Song, Yan Guo, Tongwei Jiang
Journal of Clinical Neuroscience.2024; 126: 12. CrossRef - Melatonin and gut microbiome
N. E. Garashchenko, N. V. Semenova, L. I. Kolesnikova
Acta Biomedica Scientifica.2024; 9(2): 12. CrossRef - Insights into the Mechanisms of Action of Akkermansia muciniphila in the Treatment of Non-Communicable Diseases
Honorata Mruk-Mazurkiewicz, Monika Kulaszyńska, Wiktoria Czarnecka, Albert Podkówka, Natalia Ekstedt, Piotr Zawodny, Anna Wierzbicka-Woś, Wojciech Marlicz, Błażej Skupin, Ewa Stachowska, Igor Łoniewski, Karolina Skonieczna-Żydecka
Nutrients.2024; 16(11): 1695. CrossRef - Sleep Deprivation Induces Gut Damage via Ferroptosis
Zi‐Jian Zheng, Hai‐Yi Zhang, Ya‐Lin Hu, Yan Li, Zhi‐Hong Wu, Zhi‐Peng Li, Dong‐Rui Chen, Yang Luo, Xiao‐Jing Zhang, Cang Li, Xiao‐Yu Wang, Dan Xu, Wei Qiu, Hong‐Ping Li, Xiao‐Ping Liao, Hao Ren, Jian Sun
Journal of Pineal Research.2024;[Epub] CrossRef - Enhanced cerebral blood flow similarity of the somatomotor network in chronic insomnia: Transcriptomic decoding, gut microbial signatures and phenotypic roles
Xiaofen Ma, Junle Li, Yuping Yang, Xiaofan Qiu, Jintao Sheng, Ningke Han, Changwen Wu, Guang Xu, Guihua Jiang, Junzhang Tian, Xuchu Weng, Jinhui Wang
NeuroImage.2024; 297: 120762. CrossRef - Modifications in the Composition of the Gut Microbiota in Rats Induced by Chronic Sleep Deprivation: Potential Relation to Mental Disorders
Li-Ming Zheng, Yan Li
Nature and Science of Sleep.2024; Volume 16: 1313. CrossRef - Melatonin feeding changed the microbial diversity and metabolism of the broiler cecum
Li Zhen, Yi Huang, Xuewen Bi, Anyu Gao, Linlin Peng, Yong Chen
Frontiers in Microbiology.2024;[Epub] CrossRef - Microbial melatonin metabolism in the human intestine as a therapeutic target for dysbiosis and rhythm disorders
Petra Zimmermann, Salome Kurth, Benoit Pugin, Nicholas A. Bokulich
npj Biofilms and Microbiomes.2024;[Epub] CrossRef -
The role of the probiotic
Akkermansia muciniphila
in brain functions: insights underpinning therapeutic potential
Ruiling Xu, Yuxuan Zhang, Shurui Chen, Yaohui Zeng, Xuan Fu, Ti Chen, Shilin Luo, Xiaojie Zhang
Critical Reviews in Microbiology.2023; 49(2): 151. CrossRef - The relationship between gut microbiota and inflammatory response, learning and memory in mice by sleep deprivation
Mengjie Zhang, Mengying Zhang, Guangning Kou, Yan Li
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef - Neurodegenerative and Neurodevelopmental Diseases and the Gut-Brain Axis: The Potential of Therapeutic Targeting of the Microbiome
Brian Bicknell, Ann Liebert, Thomas Borody, Geoffrey Herkes, Craig McLachlan, Hosen Kiat
International Journal of Molecular Sciences.2023; 24(11): 9577. CrossRef - Melatonin: Facts, Extrapolations and Clinical Trials
J. A. Boutin, D. J. Kennaway, R. Jockers
Biomolecules.2023; 13(6): 943. CrossRef - Potential of Akkermansia muciniphila and its outer membrane proteins as therapeutic targets for neuropsychological diseases
Fenghua Zhang, Dali Wang
Frontiers in Microbiology.2023;[Epub] CrossRef - The brain-gut-microbiota axis in the treatment of neurologic and psychiatric disorders
Maria Fernanda Naufel, Giselle de Martin Truzzi, Caroline Marcantonio Ferreira, Fernando Morgadinho Santos Coelho
Arquivos de Neuro-Psiquiatria.2023; 81(07): 670. CrossRef - Akkermansia muciniphila in neuropsychiatric disorders: friend or foe?
Wenhui Lei, Yiwen Cheng, Jie Gao, Xia Liu, Li Shao, Qingming Kong, Nengneng Zheng, Zongxin Ling, Weiming Hu
Frontiers in Cellular and Infection Microbiology.2023;[Epub] CrossRef - Targeting microbiota to alleviate the harm caused by sleep deprivation
Hongyu Chen, Chen Wang, Junying Bai, Jiajia Song, Linli Bu, Ming Liang, Huayi Suo
Microbiological Research.2023; 275: 127467. CrossRef - Targeting the blood–brain barrier to delay aging-accompanied neurological diseases by modulating gut microbiota, circadian rhythms, and their interplays
Yanping Wang, Weihong Du, Xiaoyan Hu, Xin Yu, Chun Guo, Xinchun Jin, Wei Wang
Acta Pharmaceutica Sinica B.2023;[Epub] CrossRef - The mammalian gastro‐intestinal tract is a NOT a major extra‐pineal source of melatonin
David J. Kennaway
Journal of Pineal Research.2023;[Epub] CrossRef - Puerarin alleviates sleep disorders in aged mice related to repairing intestinal mucosal barrier
Qing Tao, Jinhua Zhang, Qiao liang, Shiyu Song, Shuxia Wang, Xiaoming Yao, Qian Gao, Lei Wang
Natural Products and Bioprospecting.2023;[Epub] CrossRef - Protective and therapeutic potential of melatonin against intestinal diseases: updated review of current data based on molecular mechanisms
Saeed Mehrzadi, Mohammad Sheibani, Fereshteh Koosha, Nazila Alinaghian, Mohammad Hossein Pourhanifeh, Seid Amir Pasha Tabaeian, Russel J. Reiter, Azam Hosseinzadeh
Expert Review of Gastroenterology & Hepatology.2023; 17(10): 1011. CrossRef - Melatonin Ameliorates Neuropsychiatric Behaviors, Gut Microbiome, and Microbiota-Derived Metabolites in Rats with Chronic Sleep Deprivation
Bingcong Li, Yin-Ru Hsieh, Wen-De Lai, Te-Hsuan Tung, Yu-Xuan Chen, Chia-Hui Yang, Yu-Chiao Fang, Shih-Yi Huang
International Journal of Molecular Sciences.2023; 24(23): 16820. CrossRef - Melatonin as a Mediator of the Gut Microbiota–Host Interaction: Implications for Health and Disease
María-Ángeles Bonmatí-Carrión, Maria-Angeles Rol
Antioxidants.2023; 13(1): 34. CrossRef - Administration of Aspergillus oryzae suppresses DSS-induced colitis
Ryo Nomura, Sho Tsuzuki, Takaaki Kojima, Mao Nagasawa, Yusuke Sato, Masayoshi Uefune, Yasunori Baba, Toshiya Hayashi, Hideo Nakano, Masashi Kato, Motoyuki Shimizu
Food Chemistry: Molecular Sciences.2022; 4: 100063. CrossRef - The interplay between sleep and gut microbiota
Mengqi Han, Shiying Yuan, Jiancheng Zhang
Brain Research Bulletin.2022; 180: 131. CrossRef - Melatonin Mitigates Oxazolone-Induced Colitis in Microbiota-Dependent Manner
Zi-xiao Zhao, Xi Yuan, Yan-yan Cui, Jun Liu, Jing Shen, Bi-ying Jin, Bing-cheng Feng, Yun-jiao Zhai, Meng-qi Zheng, Guan-jun Kou, Ru-chen Zhou, Li-xiang Li, Xiu-li Zuo, Shi-yang Li, Yan-qing Li
Frontiers in Immunology.2022;[Epub] CrossRef - Human Fecal Microbiota Transplantation Reduces the Susceptibility to Dextran Sulfate Sodium-Induced Germ-Free Mouse Colitis
Yapeng Yang, Xiaojiao Zheng, Yuqing Wang, Xiang Tan, Huicong Zou, Shuaifei Feng, Hang Zhang, Zeyue Zhang, Jinhui He, Bota Cui, Xueying Zhang, Zhifeng Wu, Miaomiao Dong, Wei Cheng, Shiyu Tao, Hong Wei
Frontiers in Immunology.2022;[Epub] CrossRef - Circadian Rhythms and Melatonin Metabolism in Patients With Disorders of Gut-Brain Interactions
Sophie Fowler, Emily C. Hoedt, Nicholas J. Talley, Simon Keely, Grace L. Burns
Frontiers in Neuroscience.2022;[Epub] CrossRef - Sleep Deficiency Is Associated With Exacerbation of Symptoms and Impairment of Anorectal and Autonomic Functions in Patients With Functional Constipation
Jie Liu, Wei Wang, Jiashuang Tian, Chaolan Lv, Yuhan Fu, Ronnie Fass, Gengqing Song, Yue Yu
Frontiers in Neuroscience.2022;[Epub] CrossRef - The melatonergic agonist agomelatine ameliorates high fat diet-induced obesity in mice through the modulation of the gut microbiome
Patricia Diez-Echave, Teresa Vezza, Francesca Algieri, Antonio Jesús Ruiz-Malagón, Laura Hidalgo-García, Federico García, Rocío Morón, Manuel Sánchez, Marta Toral, Miguel Romero, Juan Duarte, José Garrido-Mesa, María Elena Rodríguez-Cabezas, Alba Rodrígue
Biomedicine & Pharmacotherapy.2022; 153: 113445. CrossRef - Melatonin protects against body weight gain induced by sleep deprivation in mice
Shuang Hu, Xuan Liu, Yuefan Wang, Rong Zhang, Shougang Wei
Physiology & Behavior.2022; 257: 113975. CrossRef - Is Melatonin the “Next Vitamin D”?: A Review of Emerging Science, Clinical Uses, Safety, and Dietary Supplements
Deanna M. Minich, Melanie Henning, Catherine Darley, Mona Fahoum, Corey B. Schuler, James Frame
Nutrients.2022; 14(19): 3934. CrossRef - Intestinal microbiota and melatonin in the treatment of secondary injury and complications after spinal cord injury
Yiwen Zhang, Rui Lang, Shunyu Guo, Xiaoqin Luo, Huiting Li, Cencen Liu, Wei Dong, Changshun Bao, Yang Yu
Frontiers in Neuroscience.2022;[Epub] CrossRef - Melatonin–Microbiome Two-Sided Interaction in Dysbiosis-Associated Conditions
Mara Ioana Iesanu, Carmen Denise Mihaela Zahiu, Ioana-Alexandra Dogaru, Diana Maria Chitimus, Gratiela Gradisteanu Pircalabioru, Suzana Elena Voiculescu, Sebastian Isac, Felicia Galos, Bogdan Pavel, Siobhain M. O’Mahony, Ana-Maria Zagrean
Antioxidants.2022; 11(11): 2244. CrossRef - Altered functional connectivity strength in chronic insomnia associated with gut microbiota composition and sleep efficiency
Ziwei Chen, Ying Feng, Shumei Li, Kelei Hua, Shishun Fu, Feng Chen, Huiyu Chen, Liping Pan, Caojun Wu, Guihua Jiang
Frontiers in Psychiatry.2022;[Epub] CrossRef - Melatonin Is Neuroprotective in Escherichia coli Meningitis Depending on Intestinal Microbiota
Dong Zhang, Shu Xu, Hucong Wu, Jiaqi Liu, Yiting Wang, Guoqiang Zhu
International Journal of Molecular Sciences.2022; 24(1): 298. CrossRef - Melatonin and Cancer: A Polyhedral Network Where the Source Matters
Maria-Angeles Bonmati-Carrion, Antonia Tomas-Loba
Antioxidants.2021; 10(2): 210. CrossRef - Changes in gut microbiota composition and their associations with cortisol, melatonin and interleukin 6 in patients with chronic insomnia
AA Masyutina, LN Gumenyuk, YuV Fatovenko, LE Sorokina, SS Bayramova, AI Alekseenko, YuV Shavrov, AA Romanova, DI Seydametova
Bulletin of Russian State Medical University.2021;[Epub] CrossRef - Microbiota Modulates Cardiac Transcriptional Responses to Intermittent Hypoxia and Hypercapnia
Dan Zhou, Jin Xue, Yukiko Miyamoto, Orit Poulsen, Lars Eckmann, Gabriel G. Haddad
Frontiers in Physiology.2021;[Epub] CrossRef
- Advances in molecular mechanisms and therapeutic strategies for central nervous system diseases based on gut microbiota imbalance
- 13,896 View
- 283 Download
- 45 Web of Science
- 43 Crossref
- Colorectal neoplasia
- Factors associated with the survival of colorectal cancer in Mexico
- Carlos Quezada-Gutiérrez, María Teresa Álvarez-Bañuelos, Jaime Morales-Romero, Clara Luz Sampieri, Raúl Enrique Guzmán-García, Evangelina Montes-Villaseñor
- Intest Res 2020;18(3):315-324. Published online May 19, 2020
- DOI: https://doi.org/10.5217/ir.2019.09179
-
Abstract
PDFPubReaderePub
- Background/Aims
Colorectal cancer (CRC) is a public health problem. In Mexico, there have been no recent studies conducted on survival in terms of this pathology or on the influence of prognostic factors. The study aims to determine the probability of survival in patients with CRC presence of low levels of schooling and a rural population, adjusted for clinical stage and type of treatment.
Methods
A retrospective study was conducted in a cohort of 305 patients with CRC treated at State Cancer Center, located in Veracruz-Mexico; the follow-up period of 60 months (2012–2016). The survival probability was calculated using the Kaplan-Meier estimator and the log-rank test with 95% confidence intervals (CIs). Prognostic factors were determined using hazard ratio (HR) multivariate Cox regression analysis.
Results
Overall survival was 40% at 60 months. Subjects in the age group ≥ 65 years had a low survival rate of 28% (P= 0.026) and an advanced clinical stage of 22% (P< 0.001). Of the patients with bone metastasis, none survived longer than 5 years (P= 0.008). With respect to the unfavorable prognostic factors identified in the multivariate analysis, a decreased level of schooling was associated with an HR of 7.6 (95% CI, 1.1–54.7), advanced clinical stage was associated with an HR of 2.1 (95% CI, 1.2–4.0), and the presence of metastasis had an HR of 1.8 (95% CI, 1.1–2.9).
Conclusions
Poor prognostic factors include an advanced clinical stage, the presence of metastasis and a low level of schooling. These findings confirm the importance of screening for early diagnosis, diminishing the barriers to accessing treatment and prospectively monitoring the population. -
Citations
Citations to this article as recorded by- Colorectal cancer survival in Mexico: Leveraging a national health insurance database
Susana Lozano-Esparza, Hugo Rodrigo Sánchez-Blas, Fidel David Huitzil-Meléndez, Mónica Isabel Meneses-Medina, Katherine Van Loon, Michael B. Potter, Alejandro Mohar, Martin Lajous
Cancer Epidemiology.2025; 94: 102698. CrossRef - Colorectal cancer survival disparities in the five regions of Georgia
Meng-Han Tsai, Daramola N. Cabral, Caitlyn Grunert, Justin X. Moore, Hong Qin
PLOS ONE.2024; 19(3): e0301027. CrossRef - Cancer Screening in Low- and Middle-Income Countries
Maria Elena Martinez, Kathleen M. Schmeler, Martin Lajous, Lisa A. Newman
American Society of Clinical Oncology Educational Book.2024;[Epub] CrossRef - Chemo-radiotherapy with 177Lu-PLGA(RGF)-CXCR4L for the targeted treatment of colorectal cancer
Pedro Cruz-Nova, Brenda Gibbens-Bandala, Alejandra Ancira-Cortez, Gerardo Ramírez-Nava, Clara Santos-Cuevas, Myrna Luna-Gutiérrez, Blanca Ocampo-García
Frontiers in Medicine.2023;[Epub] CrossRef - Pan gourmet a base de harina de trigo, linaza y chapulín (Sphenarium purpurascens) como alimento funcional
P.F Gomez- Galicia, I. Parola-Contreras, Juan Gabriel Báez- González, R. Durán-Lugo
Investigación y Desarrollo en Ciencia y Tecnología de Alimentos.2023; 8(1): 379. CrossRef - Correlations between Demographic, Clinical, and Paraclinical Variables and Outcomes in Patients with KRAS-Mutant or KRAS Wild-Type Metastatic Colorectal Cancer—A Retrospective Study from a Tertiary-Level Center in Romania
Edvina Elena Pîrvu, Emilia Severin, Raluca Ileana Pătru, Irina Niță, Stefania Andreea Toma, Roxana Rodica Macarie, Cristina Elena Cocioabă, Ioana Florescu, Simona Coniac
Diagnostics.2023; 13(18): 2930. CrossRef - Immune profile by multiplexed immunohistochemistry associated with recurrence after chemoradiation in rectal cancer
Seung Wook Hong, Seohyun Lee, Yun Jae Kim, Soyeon Ahn, In Ja Park, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jaeil Kim, Sang‐Yeob Kim, Seung‐Jae Myung
Journal of Gastroenterology and Hepatology.2022; 37(3): 542. CrossRef - Comparison of Two Types of 1-L Polyethylene Glycol-ascorbic Acid as Colonoscopic Bowel Preparation: A Prospective Randomized Study
Suh Hyun Choi, Won Eui Yoon, Seung Hyuk Kim, Hee Jun Myung, Seo Hyun Kim, Soon Oh So, Se Hun Kim, Hyun Mi Lee, Yeoun Jung Oh, Jeong Seop Moon, Tae Yeong Park, You Sun Kim
The Korean Journal of Gastroenterology.2022; 80(2): 85. CrossRef - Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef - Education levels and survival in colorectal cancer: is there really an obvious association?
Bruna Valiati, Rodrigo Oliva Perez, Paulo Gustavo Kotze
Intestinal Research.2020; 18(3): 247. CrossRef
- Colorectal cancer survival in Mexico: Leveraging a national health insurance database
- 7,516 View
- 177 Download
- 11 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Concordance between tuberculin skin test and interferon-gamma release assay for latent tuberculosis screening in inflammatory bowel disease
- Saad Alrajhi, Pascale Germain, Myriam Martel, Peter Lakatos, Talat Bessissow, Talal Al-Taweel, Waqqas Afif
- Intest Res 2020;18(3):306-314. Published online March 20, 2020
- DOI: https://doi.org/10.5217/ir.2019.00116
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Latent tuberculosis screening is mandatory prior to initiating anti-tumor necrosis factor (anti-TNF) medications. Guidelines recommend interferon-gamma release assays (IGRA) as first line screening method for the general population. Studies provided conflicting evidence on IGRA and tuberculin skin test (TST) performance in inflammatory bowel disease (IBD) patients. We assessed test concordance and the effects of immunosuppression on their performance in IBD patients.
Methods
We searched MEDLINE, Embase and Cochrane databases (2011–2018) for studies testing TST and IGRA in IBD. Primary outcome was TST and IGRA concordance. Secondary outcomes were effects of immunosuppressive therapy on performance. Immunosuppression defined as either steroids, thiopurine, methotrexate or cyclosporine use. We used the pooled random effects model to adjust for heterogeneity analyzed using (I2–Q statistics). We compared the fixed model to exclude smaller study effects.
Results
Sixteen studies (2,488 patients) were included. Pooled TST and IGRA concordance was 85% (95% confidence interval [CI], 81%–88%; P=0.01). Effects of immunosuppression were reported in 8 studies (814 patients). The odds ratio of testing positive by IGRA decreased to 0.57 if immunosuppressed (95% CI, 0.31–1.03; P=0.06). The odds ratio of testing positive by TST if immunosuppressed was 1.14 (95% CI, 0.61–2.12; P=0.69). The fixed model yielded similar results, however the negative effect of immunosuppression on IGRA reached statistical significance (P=0.01).
Conclusions
While concordance was 85% between TST and IGRA, the performance of IGRA seems to be negatively affected by immunosuppression. Given the importance of detecting latent tuberculosis prior to anti-TNF initiation, further randomized controlled trials comparing the performance of TST and IGRA in IBD patients are needed. -
Citations
Citations to this article as recorded by- Association of Latent Tuberculosis and Vitamin D Levels in Young Individuals: An Exploratory Study
Priyanka, Parul Bhatt, Ayushi Kaur Bedi, Mandira Varma Basil, Monika Sharma, Sadhna Sharma
The International Journal of Mycobacteriology.2025; 14(1): 66. CrossRef - Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef - Impact of Immunosuppressive Therapy on the Performance of Latent Tuberculosis Screening Tests in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Chan Hyuk Park, Jung Ho Park, Yoon Suk Jung
Journal of Personalized Medicine.2022; 12(3): 507. CrossRef - The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
Myeong Geun Choi, Byong Duk Ye, Suk-Kyun Yang, Tae Sun Shim, Kyung-Wook Jo, Sang Hyoung Park
Journal of Korean Medical Science.2022;[Epub] CrossRef - Prophylactic Antitubercular Therapy Is Associated With Accelerated Disease Progression in Patients With Crohn's Disease Receiving Anti-TNF Therapy: A Retrospective Multicenter Study
Fen Liu, Jian Tang, Lingna Ye, Jinyu Tan, Yun Qiu, Fan Hu, Jinshen He, Baili Chen, Yao He, Zhirong Zeng, Ren Mao, Qian Cao, Xiang Gao, Minhu Chen
Clinical and Translational Gastroenterology.2022; 13(6): e00493. CrossRef - Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef - Latent and Active Tuberculosis Infection in Patients with Inflammatory Bowel Disease
Byung Chul Jin, Hee Jin Moon, Sang Wook Kim
The Korean Journal of Gastroenterology.2022; 80(2): 72. CrossRef - Differentiating between Intestinal Tuberculosis and Crohn’s Disease May Be Complicated by Multidrug-resistant Mycobacterium tuberculosis
Seung Wook Hong, Sang Hyoung Park, Byong Duk Ye, Suk-Kyun Yang
The Ewha Medical Journal.2021; 44(3): 93. CrossRef - Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea
Jae Yong Lee, Kyunghwan Oh, Hee Seung Hong, Kyuwon Kim, Seung Wook Hong, Jin Hwa Park, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Ho-Su Lee, Kyung-Wook Jo, Sang Hyoung Park
BMC Gastroenterology.2021;[Epub] CrossRef - Is Multidrug-resistant Extrapulmonary Tuberculosis Important? If So, What Is Our Strategy?
Seong-Eun Kim
The Ewha Medical Journal.2021; 44(4): 148. CrossRef
- Association of Latent Tuberculosis and Vitamin D Levels in Young Individuals: An Exploratory Study
- 6,397 View
- 148 Download
- 11 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Hypermethylated promoters of tumor suppressor genes were identified in Crohn’s disease patients
- Tae-Oh Kim, Yu Kyeong Han, Joo Mi Yi
- Intest Res 2020;18(3):297-305. Published online February 7, 2020
- DOI: https://doi.org/10.5217/ir.2019.00105
-
Abstract
PDFPubReaderePub
- Background/Aims
Overwhelming evidence suggests that inflammatory bowel disease (IBD) is caused by a complicated interplay between the multiple genes and abnormal epigenetic regulation in response to environmental factors. It is becoming apparent that epigenetic factors are significantly associated with the development of the disease. DNA methylation remains the most studied epigenetic modification, and hypermethylation of gene promoters is associated with gene silencing.
Methods
DNA methylation alterations may contribute to the many complex diseases development by regulating the interplay between external and internal environmental factors and gene transcriptional expression. In this study, we used 15 tumor suppressor genes (TSGs), originally identified in colon cancer, to detect promoter methylation in patients with Crohn’s disease (CD). Methylation specific polymerase chain reaction and bisulfite sequencing analyses were performed to assess methylation level of TSGs in CD patients.
Results
We found 6 TSGs (sFRP1, sFRP2, sFRP5, TFPI2, Sox17, and GATA4) are robustly hypermethylated in CD patient samples. Bisulfite sequencing analysis confirmed the methylation levels of the sFRP1, sFRP2, sFRP5, TFPI2, Sox17, and GATA4 promoters in the representative CD patient samples.
Conclusions
In this study, the promoter hypermethylation of the TSGs observed indicates that CD exhibits specific DNA methylation signatures with potential clinical applications for the noninvasive diagnosis of IBD and the prognosis for patients with IBD. -
Citations
Citations to this article as recorded by- Effects of DNA methylation and its application in inflammatory bowel disease (Review)
Francis Akanyibah, Yi Zhu, Aijun Wan, Dickson Ocansey, Yuxuan Xia, An-Ning Fang, Fei Mao
International Journal of Molecular Medicine.2024;[Epub] CrossRef - Transcriptomic Module Discovery of Diarrhea-Predominant Irritable Bowel Syndrome: A Causal Network Inference Approach
Davide Guido, Fatima Maqoud, Michelangelo Aloisio, Domenica Mallardi, Blendi Ura, Nicolò Gualandi, Massimiliano Cocca, Francesco Russo
International Journal of Molecular Sciences.2024; 25(17): 9322. CrossRef - From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies
Ehsan Gharib, Gilles A. Robichaud
International Journal of Molecular Sciences.2024; 25(17): 9463. CrossRef - Inflammatory Bowel Diseases in Spain: A View from the Present to the Future
Raquel Francés, Yuanji Fu, Christophe Desterke, Jorge Mata-Garrido
J.2024; 7(4): 489. CrossRef - Epigenotoxicity: a danger to the future life
Farzaneh Kefayati, Atoosa Karimi Babaahmadi, Taraneh Mousavi, Mahshid Hodjat, Mohammad Abdollahi
Journal of Environmental Science and Health, Part A.2023; 58(4): 382. CrossRef - Evaluating the Clinical Performance of a Dual-Target Stool DNA Test for Colorectal Cancer Detection
Zhongxin Wang, Jian Shang, Guannan Zhang, Lingjun Kong, Feng Zhang, Ye Guo, Yaling Dou, Jun Lin
The Journal of Molecular Diagnostics.2022; 24(2): 131. CrossRef - Lipocalin 2 potentially contributes to tumorigenesis from colitis via IL-6/STAT3/NF-κB signaling pathway
Se Lim Kim, Min Woo Shin, Seung Young Seo, Sang Wook Kim
Bioscience Reports.2022;[Epub] CrossRef - Personalized medicine in inflammatory bowel disease: Perspectives on Asia
Su Hyun Park, Sang Hyoung Park
Journal of Gastroenterology and Hepatology.2022; 37(8): 1434. CrossRef - Landscape of sialylation patterns identify biomarkers for diagnosis and prediction of response to anti-TNF therapy in crohn’s disease
Chenglin Ye, Sizhe Zhu, Yuan Gao, Yabing Huang
Frontiers in Genetics.2022;[Epub] CrossRef - The role of epigenetic modifications for the pathogenesis of Crohn's disease
M. Hornschuh, E. Wirthgen, M. Wolfien, K. P. Singh, O. Wolkenhauer, J. Däbritz
Clinical Epigenetics.2021;[Epub] CrossRef - SFRP5 inhibits melanin synthesis of melanocytes in vitiligo by suppressing the Wnt/β-catenin signaling
Dao-Pei Zou, Yang-Mei Chen, Ling-Zhao Zhang, Xiao-Hui Yuan, Yu-Jie Zhang, Adelina Inggawati, Pham Thi Kieu Nguyet, Tian-Wen Gao, Jin Chen
Genes & Diseases.2021; 8(5): 677. CrossRef
- Effects of DNA methylation and its application in inflammatory bowel disease (Review)
- 6,653 View
- 139 Download
- 10 Web of Science
- 11 Crossref
- Inflammatory bowel diseases
- Presentation and outcomes among inflammatory bowel disease patients with concurrent pneumatosis intestinalis: a case series and systematic review
- Youran Gao, Meka Uffenheimer, Michael Ashamallah, Gregory Grimaldi, Arun Swaminath, Keith Sultan
- Intest Res 2020;18(3):289-296. Published online November 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00073
-
Abstract
PDFPubReaderePub
- Background/Aims
Inflammatory bowel disease (IBD) involves chronic inflammation of the colon with ulcerative colitis (UC), and the colon and/or small intestine with Crohn’s disease (CD). Pneumatosis intestinalis (PI), characterized by compromise of the intestinal wall with gas-filled cysts, has rarely been reported with IBD. The presentation, best management and outcomes of PI with IBD are poorly defined.
Methods
We conducted a search for PI in all abdominal computed tomography (CT) reports at 2 large tertiary care hospitals from January 1, 2010 to December 31, 2017, cross referenced to ICD codes for IBD. CT and chart review was performed to confirm PI and IBD respectively. A systematic review excluding case reports was performed for PI with IBD for comparison.
Results
Of 5,990 patients with a CT abdomen report mentioning PI, we identified 11 cases of PI with IBD, 4 UC, 6 CD, and 1 indeterminate colitis. PI was limited to the small bowel in 5 patients, the right colon in 5, and small bowel and colonic in 1. All 3 mortalities had CD, small intestinal PI and portal/mesenteric venous gas. The systematic literature search identified 9 articles describing 58 patients with IBD and PI. These cases were mostly included in larger cohorts of PI patients without extractable data on presentation or outcomes in the IBD subpopulation.
Conclusions
Ours appears to be the first reporting of presentations and outcomes, outside of case reports, for those with PI and IBD. The high mortality for those with CD and PI of the small bowel appears to define a group requiring more than supportive medical care. -
Citations
Citations to this article as recorded by- Teasing out factors differentiating pathologic from benign pneumatosis intestinalis
Julia Song, Biqi Zhang, David Mahvi, Mahsa Shariat, Manuel Castillo-Angeles, Tanujit Dey, Reza Askari
Journal of Trauma and Acute Care Surgery.2025; 98(5): 806. CrossRef - MR Enterography in Ulcerative Colitis: Beyond Endoscopy
Amir Reza Radmard, Mehrnam Amouei, Ala Torabi, Ali Reza Sima, Hiva Saffar, Amine Geahchan, Amir H. Davarpanah, Bachir Taouli
RadioGraphics.2024;[Epub] CrossRef - Plaque-like Mucosal Change in Pneumatosis Intestinalis with Ulcerative Colitis
Atsushi Ikehata, Machi Kiyohara, Sadahide Ono, Takashi Kajiwara
Internal Medicine.2024; 63(17): 2467. CrossRef - The Challenge of Pneumatosis Intestinalis: A Contemporary Systematic Review
Gennaro Perrone, Mario Giuffrida, Valentina Donato, Gabriele Luciano Petracca, Giorgio Rossi, Giacomo Franzini, Sara Cecconi, Alfredo Annicchiarico, Elena Bonati, Fausto Catena
Journal of Personalized Medicine.2024; 14(2): 167. CrossRef - Pneumatosis Intestinalis Manifesting as an Atypical Presentation of Crohn’s Disease
Charles Vallejo, Yousra Gheit, Talwinder K Nagi, Zoilo K Suarez, Muhammad Haider, Touqir Zahra
Cureus.2024;[Epub] CrossRef - The spectrum of pneumatosis intestinalis in the adult. A surgical dilemma
Giuseppe Tropeano, Marta Di Grezia, Caterina Puccioni, Valentina Bianchi, Gilda Pepe, Valeria Fico, Gaia Altieri, Giuseppe Brisinda
World Journal of Gastrointestinal Surgery.2023; 15(4): 553. CrossRef - Neumoperitoneo secundario a neumatosis intestinal masiva: un reporte de caso
David Charry-Borrero, Yesica Ascanio-Quintero, Juan Rodríguez-Valenzuela, Faure Yezid Rodríguez-Velásquez, Juan Felipe Coronado-Sarmiento, Eduardo Tuta-Quintero
Revista Colombiana de Cirugía.2023;[Epub] CrossRef - Idiopathic asymptomatic pneumoperitoneum in a patient with ureteric calculus and Crohn’s disease
Gitte Grunnet Raabe, Benedicte Schelde-Olesen, Thomas Bjørsum-Meyer
Journal of Surgical Case Reports.2022;[Epub] CrossRef - Pneumatosis Intestinalis Induced by Anticancer Treatment: A Systematic Review
Gianluca Gazzaniga, Federica Villa, Federica Tosi, Elio Gregory Pizzutilo, Stefano Colla, Stefano D’Onghia, Giusy Di Sanza, Giulia Fornasier, Michele Gringeri, Maria Victoria Lucatelli, Giulia Mosini, Arianna Pani, Salvatore Siena, Francesco Scaglione, An
Cancers.2022; 14(7): 1666. CrossRef - Pneumatosis Intestinalis Induced by Alpha-Glucosidase Inhibitors in Patients with Diabetes Mellitus
Blake J. McKinley, Mariangela Santiago, Christi Pak, Nataly Nguyen, Qing Zhong
Journal of Clinical Medicine.2022; 11(19): 5918. CrossRef
- Teasing out factors differentiating pathologic from benign pneumatosis intestinalis
- 6,259 View
- 148 Download
- 9 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Safety of tumor necrosis factor inhibitor use in patients with concomitant malignancy
- Hiep Phan, Rick A. Weideman, Daisha J. Cipher, Linda A. Feagins
- Intest Res 2020;18(3):282-288. Published online April 7, 2020
- DOI: https://doi.org/10.5217/ir.2019.09140
-
Abstract
PDFPubReaderePub
- Background/Aims
Safety for tumor necrosis factor inhibitors (TNFi) in cancer has been focused on risk of incident malignancies, but studies on prognostic effects have been scarce. We determined survival and recurrence rates at 1, 2, and 5 years after cancer diagnosis in patients with and without concurrent TNFi use.
Methods
Chart reviews were performed between 1996 and 2015 at the VA North Texas Healthcare System. Cases were patients with inflammatory disease, concomitant malignancy, and TNFi use while controls were patients with inflammatory disease, concomitant malignancy but no TNFi use. Cases and controls were matched for type of malignancy. Analysis was performed with log-rank tests on Kaplan-Meier curves.
Results
Thirty-six cases and 72 controls were identified. For cases, survival at 1, 2, and 5 years were 32 (89%), 31 (86%), and 29 (81%) compared to 63 (90%), 61 (87%), and 51 (73%) for the control group (P=0.985). For cases, recurrence rates at 1, 2, and 5 years were 3 (8%), 5 (14%), and 6 (17%) compared to 2 (3%), 5 (7%), and 7 (10%) for the control group (P=0.158).
Conclusions
Our findings suggest TNFi may be safely used in select inflammatory disease patients with concurrent cancer if therapy is needed for proper disease control. However, case-by-case consideration in conjunction with an oncologist is recommended while considering the apparent safety of TNFi for patients suffering from active inflammatory diseases despite having a concomitant malignancy. -
Citations
Citations to this article as recorded by- Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
Oh Chan Kwon, Hye Sun Lee, So Young Jeon, Min-Chan Park
Rheumatology.2025;[Epub] CrossRef - Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis
Akshita Gupta, Laurent Peyrin-Biroulet, Ashwin N. Ananthakrishnan
Clinical Gastroenterology and Hepatology.2024; 22(3): 499. CrossRef - Survival in patients with rheumatoid arthritis and early breast cancer treated with tumor necrosis factor inhibitors
Juan I. Ruiz, Xiudong Lei, Wu Chi-Fang, Sharon H. Giordano, Hui Zhao, Suja S. Rajan, Heather Lin, Maria E. Suarez-Almazor
Breast Cancer.2024; 31(6): 1059. CrossRef - Anti-tumor necrosis factor-alpha monoclonal antibody suppresses colorectal cancer growth in an orthotopic transplant mouse model
Takeshi Takasago, Ryohei Hayashi, Yoshitaka Ueno, Misa Ariyoshi, Kana Onishi, Ken Yamashita, Yuichi Hiyama, Hidehiko Takigawa, Ryo Yuge, Yuji Urabe, Shiro Oka, Yasuhiko Kitadai, Shinji Tanaka, Kenji Fujiwara
PLOS ONE.2023; 18(3): e0283822. CrossRef - Dermatofibrosarcoma Protuberans (DFSP) with Fibrosarcomatous Changes in a Patient with Crohn’s Disease Treated with Anti-TNF (Adalimumab)
Ivo Klarin, Yoshihiro Moriwaki
Case Reports in Gastrointestinal Medicine.2023; 2023: 1. CrossRef - Use of Disease-modifying Antirheumatic Drugs After Cancer Diagnosis in Rheumatoid Arthritis Patients
Young Bin Joo, Seung Min Jung, Yune-Jung Park, Ki-Jo Kim, Kyung-Su Park
Journal of Rheumatic Diseases.2022; 29(3): 162. CrossRef - Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
Jihye Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2022; 37(5): 895. CrossRef - Twenty Years of Targeted and Biologic Immunomodulatory Drugs
Julia Berman, Yarden Yavne, Yonatan Edel, Ori Elkayam, Victoria Furer, Daniel Shepshelovich
Mayo Clinic Proceedings.2022; 97(8): 1512. CrossRef - Impact of rheumatoid arthritis and biologic and targeted synthetic disease modifying antirheumatic agents on cancer risk and recurrence
Namrata Singh, Christopher I. Li
Current Opinion in Rheumatology.2021; 33(3): 292. CrossRef - Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Jihye Park, Jae Hee Cheon
Gut and Liver.2021; 15(5): 641. CrossRef
- Effect of TNF inhibitors on the risk of cancer recurrence in patients with AS: a nested case-control study
- 6,583 View
- 155 Download
- 12 Web of Science
- 10 Crossref
- Miscellaneous
- Clinical profile and outcomes of opioid abuse gastroenteropathy: an underdiagnosed disease entity
- Ramit Mahajan, Yogesh Gupta, Arshdeep Singh, Pulkit Dhiman, Vandana Midha, Chandan Kakkar, Vikram Narang, Varun Mehta, Kavita Saggar, Ajit Sood
- Intest Res 2020;18(2):238-244. Published online February 25, 2020
- DOI: https://doi.org/10.5217/ir.2019.00104
-
Abstract
PDFPubReaderePub
- Background/Aims
Opioid-induced bowel dysfunction includes nausea, vomiting, constipation and abdominal distension. We describe patients presenting with gastrointestinal (GI) ulcers and ulcerated strictures secondary to opioid abuse, an entity not well described in literature.
Methods
This retrospective observational study included patients with opioid abuse gastroenteropathy presenting to Dayanand Medical College and Hospital, Ludhiana, India between January 2013 and December 2018. Opioid abuse gastroenteropathy was defined as gastric or small bowel ulcers and ulcerated strictures in patients abusing opioids, where all other possible etiologies of GI ulcers/strictures were excluded. Clinical, biochemical, endoscopic, radiological and histological parameters as well as response to treatment were assessed.
Results
During the study period, 20 patients (mean age, 38.5±14.2 years; 100% males) were diagnosed to have opioid induced GI ulcers and/or ulcerated strictures. The mean duration of opioid consumption was 6.2±3.4 years. The mean duration of symptoms at presentation was 222.1±392.3 days. Thirteen patients (65%) had gastroduodenal involvement, 6 (30%) had a jejunoileal disease and 1 (5%) had an ileocecal stricture. Two patients (10%) presented with upper GI bleeding, 11 (55%) had features of gastric outlet obstruction and 7 (35%) presented with small bowel obstruction. Abdominal pain and iron deficiency anemia were the most common presentations. Only 1 patient (5%) responded to proton pump inhibitors, 3 (15%) had a lasting response to endoscopic balloon dilatation, while all other (80%) required surgical intervention.
Conclusions
Opioid abuse gastroenteropathy presents as ulcers and ulcerated strictures which respond poorly to medical management and endoscopic balloon dilatation. A majority of these cases need surgical intervention. -
Citations
Citations to this article as recorded by- Transdermal fentanyl induced paralytic intestinal obstruction in advanced liver cancer: a case report
Chen Li, Jindong Chu, Xiaodong Jia, Haibin Su
Frontiers in Pharmacology.2025;[Epub] CrossRef - Peptic ulcer characteristics in oral opium and non-opium user patients with upper gastrointestinal bleeding
Mohsen Masoodi, Mohammad Sabzikarian, Nikta Masoodi, Saeed Farhadi, Gholam Reza Rezamand, Seidamir Pasha Tabaeian, Atefeh Talebi, Farimah Fayyaz
BMC Gastroenterology.2024;[Epub] CrossRef - Cryptogenic multifocal ulcerous stenosing enteritis: A ray of light on the umbra of the dark continent
Mithu Bhowmick, Vishal Sharma
Indian Journal of Gastroenterology.2024; 43(6): 1082. CrossRef - Analgesic and Proton Pump Inhibitor Combinations in Prescriptions: An Insights from the Southeastern Region of Bangladesh
Md Abdus Samadd, Ashfia Tasnim Munia, Most. Jannatun Ferdousi, K. M. Yasif Kayes Sikdar, Mohammad Ashraful Islam, A. S. M. Monjur Al Hossain, Md. Raihan Sarkar
Malaysian Journal of Medicine and Health Sciences.2024; 20(4): 107. CrossRef - Adult‐onset megacolon with focal hypoganglionosis: A detailed phenotyping and prospective cohort study
Jiyoung Yoon, Kee Wook Jung, Nam Seok Ham, Jihun Kim, Yoon Suh Do, Seon Ok Kim, Sang Hyun Choi, Dong Wook Kim, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Yong Sik Yoon, Chan Wook Kim, Chang Sik Yu, Hwoon‐Yong Jung, S
Neurogastroenterology & Motility.2023;[Epub] CrossRef - Endogenous opiates and behavior: 2020
Richard J. Bodnar
Peptides.2022; 151: 170752. CrossRef
- Transdermal fentanyl induced paralytic intestinal obstruction in advanced liver cancer: a case report
- 10,400 View
- 177 Download
- 5 Web of Science
- 6 Crossref
- Endoscopy
- Prototype single-balloon enteroscopy with passive bending and high force transmission improves depth of insertion in the small intestine
- Yasuhiro Morita, Shigeki Bamba, Osamu Inatomi, Kenichiro Takahashi, Takayuki Imai, Masaki Murata, Masashi Ohno, Masaya Sasaki, Tomoyuki Tsujikawa, Akira Andoh
- Intest Res 2020;18(2):229-237. Published online April 9, 2020
- DOI: https://doi.org/10.5217/ir.2019.09150
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
We retrospectively analyzed Crohn’s disease (CD) patients with small intestinal strictures who underwent single-balloon enteroscopy (SBE) to ascertain whether prototype SBEs with a passive bending mechanism and high force transmission insertion tube had better insertability in the small intestine than a conventional SBE.
Methods
Among 253 CD patients who underwent SBE, we identified 94 CD patients who had undergone attempted endoscopic balloon dilatation (EBD) for small intestinal stenosis for inclusion in this study. We analyzed whether the type of scope used for their initial procedure affected the cumulative surgery-free rate. For the insertability analysis, patients who underwent SBE at least twice were divided into 3 groups according to the type of scope used: conventional SBE only, prototype SBE only, and both conventional and prototype SBEs. For each group, depth of insertion, procedure time, and number of EBDs were compared in the same patient at different time points.
Results
The success rate of EBD was 88.3%. The 5- and 10-year cumulative surgery-free rate was 75.7% and 72.8%, respectively. Cox regression analysis indicated that the factors contributing to surgery were long stricture (≥2 cm), EBD failure, and elevated Crohn’s Disease Activity Index, but not the type of scope used for EBD. The prototype SBEs significantly improved the depth of insertion (P=0.03, Wilcoxon’s signed-rank test).
Conclusions
In CD patients with small intestinal stenosis, the prototype SBEs with a passive bending mechanism and high force transmission insertion tube did not improve long-term EBD outcome but did improve deep insertability. (Clinical Trial Registration No. UMIN000037102) -
Citations
Citations to this article as recorded by- Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
Masashi Ohno, Atsushi Nishida, Akinori Otsuki, Yoshihiro Yokota, Takayuki Imai, Shigeki Bamba, Osamu Inatomi
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef - Role of Device-Assisted Enteroscopy in Crohn’s Disease
Giulia Catassi, Clelia Marmo, Antonio Gasbarrini, Maria Elena Riccioni
Journal of Clinical Medicine.2024; 13(13): 3919. CrossRef - Performance of Balloon-Assisted Enteroscopy for Non-ERCP Indications in Patients with Surgically Altered Gastrointestinal Anatomy
Ji Hee Song, Seong Ran Jeon, Jin Su Kim, Bo-In Lee, Jin-Oh Kim, Han Hee Lee
Digestive Diseases and Sciences.2023; 68(6): 2545. CrossRef - Rebleeding Rate and Risk Factors for Rebleeding after Device-Assisted Enteroscopy in Patients with Obscure Gastrointestinal Bleeding: A KASID Multicenter Study
Yuna Kim, Jae-Hyun Kim, Eun-Ae Kang, Soo-Jung Park, Jae-Jun Park, Jae-Hee Cheon, Tae-Il Kim, Jihye Park, Seong-Ran Jeon
Diagnostics.2022; 12(4): 954. CrossRef - Intestinal stricture in Crohn's disease: A 2020 update
Xiao Xuan Lin, Yun Qiu, Xiao Jun Zhuang, Fen Liu, Xiao Min Wu, Min Hu Chen, Ren Mao
Journal of Digestive Diseases.2021; 22(7): 390. CrossRef - Factors Affecting Route Selection of Balloon-Assisted Enteroscopy in Patients with Obscure Gastrointestinal Bleeding: A KASID Multicenter Study
Dong Hoon Baek, Seonyeong Hwang, Chang Soo Eun, Seong Ran Jeon, Jinsu Kim, Eun Ran Kim, Dong-Hoon Yang, Hyun Joo Jang, Jong Pil Im, Soo Jung Park, Sung Hoon Jung
Diagnostics.2021; 11(10): 1860. CrossRef
- Leucine-rich alpha-2 glycoprotein as a superior biomarker to C-reactive protein for detecting small bowel lesions in Crohn’s disease
- 7,301 View
- 114 Download
- 6 Web of Science
- 6 Crossref
- Inflammatory bowel diseases
- Inhibition of plasminogen activator inhibitor-1 attenuates against intestinal fibrosis in mice
- Jin Imai, Takashi Yahata, Hitoshi Ichikawa, Abd Aziz Ibrahim, Masaki Yazawa, Hideaki Sumiyoshi, Yutaka Inagaki, Masashi Matsushima, Takayoshi Suzuki, Tetsuya Mine, Kiyoshi Ando, Toshio Miyata, Katsuto Hozumi
- Intest Res 2020;18(2):219-228. Published online February 17, 2020
- DOI: https://doi.org/10.5217/ir.2019.00037
-
Abstract
PDFPubReaderePub
- Background/Aims
Intestinal fibrosis is a major complication of Crohn’s disease (CD). The profibrotic protein transforming growth factor-β (TGF-β) has been considered to be critical for the induction of the fibrotic program. TGF-β has the ability to induce not only the expression of extracellular matrix (ECM) including collagen, but also the production of plasminogen activator inhibitor-1 (PAI-1) that prevents enzymatic degradation of the ECM during the onset of fibrotic diseases. However, the significance of PAI-1 in the developing intestinal fibrosis has not been fully understood. In the present study, we examined the actual expression of PAI-1 in fibrotic legion of intestinal inflammation and its correlation with the abnormal ECM deposition.
Methods
Chronic intestinal inflammation was induced in BALB/c mice using 8 repeated intrarectal injections of 2,4,6-trinitrobenzene sulfonic acid (TNBS). TM5275, a PAI-1 inhibitor, was orally administered as a carboxymethyl cellulose suspension each day for 2 weeks after the sixth TNBS injection.
Results
Using a publicly available dataset (accession number, GSE75214) and TNBS-treated mice, we observed increases in PAI-1 transcripts at active fibrotic lesions in both patients with CD and mice with chronic intestinal inflammation. Oral administration of TM5275 immediately after the onset of intestinal fibrosis upregulated MMP-9 (matrix metalloproteinase 9) and decreased collagen accumulation, resulting in attenuation of the fibrogenesis in TNBS-treated mice.
Conclusions
PAI-1-mediated fibrinolytic system facilitates collagen degradation suppression. Hence, PAI-1 inhibitor could be applied as an anti-fibrotic drug in CD treatment. -
Citations
Citations to this article as recorded by- Novel Transcriptomic Signatures in Fibrostenotic Crohn’s Disease: Dysregulated Pathways, Promising Biomarkers, and Putative Therapeutic Targets
Animesh Acharjee, Uday Shivaji, Giovanni Santacroce, Sarah Akiror, Louisa Jeffery, Csilla Varnai, Gary Reynolds, Davide Zardo, Snehali Majumder, Asma Amamou, Georgios V Gkoutos, Marietta Iacucci, Subrata Ghosh
Inflammatory Bowel Diseases.2025; 31(6): 1502. CrossRef - The role of matrix metalloproteinase 9 in fibrosis diseases and its molecular mechanisms
Yuling Wang, Linke Jiao, Caoxia Qiang, Chen Chen, Zihuan Shen, Fan Ding, Lifei Lv, Tingting Zhu, Yingdong Lu, Xiangning Cui
Biomedicine & Pharmacotherapy.2024; 171: 116116. CrossRef - Plasminogen activator inhibitor-1 promotes immune evasion in tumors by facilitating the expression of programmed cell death-ligand 1
Abd Aziz Ibrahim, Taku Fujimura, Tomoko Uno, Tomoya Terada, Ken-ichi Hirano, Hiroyuki Hosokawa, Akio Ohta, Toshio Miyata, Kiyoshi Ando, Takashi Yahata
Frontiers in Immunology.2024;[Epub] CrossRef - Fibrostenosing Crohn’s Disease: Pathogenetic Mechanisms and New Therapeutic Horizons
Irene Mignini, Valentina Blasi, Fabrizio Termite, Giorgio Esposto, Raffaele Borriello, Lucrezia Laterza, Franco Scaldaferri, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
International Journal of Molecular Sciences.2024; 25(12): 6326. CrossRef - Impact of Plasminogen Activator Inhibitor-1 Serum Levels and the -675 4G/5G Variant in the SERPINE1 Gene on Systemic Sclerosis in a Mexican Population
José Alvaro Lomelí-Nieto, José Francisco Muñoz-Valle, José Eduardo Navarro-Zarza, Christian Johana Baños-Hernández, Jesús Alberto Gutierrez-Brito, Valeria Renteria-Cabrera, Eduardo Arturo Horta-Chávez, José Javier Morales-Núñez, Samuel García-Arellano, Is
Life.2024; 14(9): 1056. CrossRef - PAI-1 siRNA-loaded biomimetic nanoparticles for ameliorating diminished ovarian reserve and inhibiting ovarian fibrosis
Hua Guo, Chang Xiao, Xinshu Li, Jialing Li, Xue Chen, Bin liu, Rong Hu
European Journal of Pharmacology.2024; : 176948. CrossRef - Metformin acts on miR-181a-5p/PAI-1 axis in stem cells providing new strategies for improving age-related osteogenic differentiation decline
Guanhao Hong, Yulan Zhou, Shukai Yang, Shouquan Yan, Jiaxu Lu, Bo Xu, Zeyu Zhan, Huasheng Jiang, Bo Wei, Jiafeng Wang
Stem Cells.2024; 42(12): 1055. CrossRef - Phytochemical Compounds as Promising Therapeutics for Intestinal Fibrosis in Inflammatory Bowel Disease: A Critical Review
Aya A. Touny, Balaji Venkataraman, Shreesh Ojha, Mauro Pessia, Veedamali S. Subramanian, Shamanth Neralagundi Hariharagowdru, Sandeep B. Subramanya
Nutrients.2024; 16(21): 3633. CrossRef - Fibro-Stenosing Crohn’s Disease: What Is New and What Is Next?
Virginia Solitano, Arianna Dal Buono, Roberto Gabbiadini, Marek Wozny, Alessandro Repici, Antonino Spinelli, Stefania Vetrano, Alessandro Armuzzi
Journal of Clinical Medicine.2023; 12(9): 3052. CrossRef - Downregulation of Heat Shock Protein 72 Contributes to Fibrostenosis in Crohn’s Disease
Seung Won Kim, Jae-Young Lee, Han Cheol Lee, Jae Bum Ahn, Ji Hyung Kim, I Seul Park, Jae Hee Cheon, Duk Hwan Kim
Gut and Liver.2023; 17(6): 905. CrossRef - Revisiting fibrosis in inflammatory bowel disease: the gut thickens
Silvia D’Alessio, Federica Ungaro, Daniele Noviello, Sara Lovisa, Laurent Peyrin-Biroulet, Silvio Danese
Nature Reviews Gastroenterology & Hepatology.2022; 19(3): 169. CrossRef - The Molecular Mechanisms of Intestinal Inflammation and Fibrosis in Crohn’s Disease
Yuki Hayashi, Hiroshi Nakase
Frontiers in Physiology.2022;[Epub] CrossRef - Attenuation of Excess TNF-α Release in Crohn’s Disease by Silencing of iRHOMs 1/2 and the Restoration of TGF-β Mediated Immunosuppression Through Modulation of TACE Trafficking
Taylor J. Louis, Ahmad Qasem, Saleh A. Naser
Frontiers in Immunology.2022;[Epub] CrossRef - ZNF281 Promotes Colon Fibroblast Activation in TGFβ1-Induced Gut Fibrosis
Ilaria Laudadio, Alex Bastianelli, Valerio Fulci, Claudia Carissimi, Eleonora Colantoni, Francesca Palone, Roberta Vitali, Elisa Lorefice, Salvatore Cucchiara, Anna Negroni, Laura Stronati
International Journal of Molecular Sciences.2022; 23(18): 10261. CrossRef - Macrophages in intestinal fibrosis and regression
Hui Yao, Guoyao Tang
Cellular Immunology.2022; 381: 104614. CrossRef - Prevention and Treatment of Stricturing Crohn’s Disease – Perspectives and Challenges
Joseph Sleiman, Sara El Ouali, Taha Qazi, Benjamin Cohen, Scott R. Steele, Mark E. Baker, Florian Rieder
Expert Review of Gastroenterology & Hepatology.2021; 15(4): 401. CrossRef - Elevated expression of plasminogen activator inhibitor (PAI-1/SERPINE1) is independent from rs1799889 genotypes in arthrofibrosis
Banu Bayram, Aaron R. Owen, Amel Dudakovic, Jacob W. Bettencourt, Afton K. Limberg, Mark E. Morrey, Joaquin Sanchez-Sotelo, Daniel J. Berry, Jean-Pierre A. Kocher, Andre J. van Wijnen, Matthew P. Abdel
Meta Gene.2021; 28: 100877. CrossRef - Molecular targets and the use of biologics in the management of small bowel fibrosis in inflammatory bowel disease
Muaad Abdulla, Thean Soon Chew
Current Opinion in Gastroenterology.2021; 37(3): 275. CrossRef - Intestinal stricture in Crohn's disease: A 2020 update
Xiao Xuan Lin, Yun Qiu, Xiao Jun Zhuang, Fen Liu, Xiao Min Wu, Min Hu Chen, Ren Mao
Journal of Digestive Diseases.2021; 22(7): 390. CrossRef - Therapeutic applications of PAI-1 inhibitor for the treatment of hematological malignancies
Takashi Yahata
Japanese Journal of Thrombosis and Hemostasis.2020; 31(3): 310. CrossRef
- Novel Transcriptomic Signatures in Fibrostenotic Crohn’s Disease: Dysregulated Pathways, Promising Biomarkers, and Putative Therapeutic Targets
- 9,712 View
- 280 Download
- 21 Web of Science
- 20 Crossref
- Inflammatory bowel diseases
- Histologically confirmed upper gastrointestinal Crohn’s disease: is it rare or are we just not searching hard enough?
- Omar Ibrahim Saadah, Kholoud Bakur Fallatah, Cedric Baumann, Abdulrahman Ahmed Elbaradie, Fatimah Talat Howladar, Motaz Tariq Daiwali, Omar Hamad Alshuaibi, Majid Abdulaziz Alsahafi, Rana Yaqoob Bokhary, Yousef Abdulfattah Qari, Laurent Peyrin-Biroulet, Mahmoud Hisham Mosli
- Intest Res 2020;18(2):210-218. Published online February 7, 2020
- DOI: https://doi.org/10.5217/ir.2019.00091
-
Abstract
PDFPubReaderePub
- Background/Aims
Crohn’s disease (CD) may involve the upper parts of the gastrointestinal (GI) tract including the esophagus, stomach, and duodenum. Clinical features of upper GI CD (UGICD) are not well characterized in the Gulf region. We therefore aimed to assess the prevalence and clinical characteristics of patients diagnosed with UGICD.
Methods
We performed a retrospective analysis of all patients diagnosed with CD who underwent upper GI endoscopy between 2012 and 2017 at King Abdulaziz University Hospital, irrespective of age. Patients who had endoscopy of the upper GI tract at baseline and had histologically confirmed UGICD were included. Data on patients’ demographics, clinical characteristics, extraintestinal manifestations and complications were reviewed.
Results
We identified 78 CD patients who underwent upper GI endoscopy from our medical records. The mean age was 17.2±8.7 years and 55.1% were males. Of the total, 19 out of 78 patients (24.4%) had histologically confirmed UGICD (3 esophageal, 16 gastric, and 9 duodenal), of which 52.6% were symptomatic. Disease distribution was ileal in 57.8%, colonic in 21.1% and ileo-colonic in 21.1%. A non-stricturing and non-penetrating phenotype was reported in 89.4%, stricturing in 5.3%, and penetrating in 5.3%. Perianal disease was found in 10.5%. UGICD was complicated by stricture formation in 2 patients (esophageal and gastric).
Conclusions
The prevalence of UGICD is considered high among CD Saudi patients who undergo upper GI endoscopy at baseline, and is asymptomatic in 47.4% of patients. This reported prevalence is not dissimilar from reports originating from Western countries. -
Citations
Citations to this article as recorded by- Focal Active Brunner Gland Lobulitis: Ignored or Yet Undetected Sign of Crohn Duodenitis?
Badr AbdullGaffar, Huda Quarishi
Advances in Anatomic Pathology.2023; 30(5): 355. CrossRef - Les maladies inflammatoires chroniques intestinales (MICI) et tube digestif haut
Denis Chatelain, Amine Moslemi, Axel Dreau, Marine Clement
Annales de Pathologie.2023; 43(3): 192. CrossRef - Bronchoesophageal fistula in a patient with Crohn’s disease receiving anti-tumor necrosis factor therapy
Kyunghwan Oh, Kee Don Choi, Hyeong Ryul Kim, Tae Sun Shim, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
Clinical Endoscopy.2023; 56(2): 239. CrossRef - A systematic review and meta‐analysis of prevalence and clinical features of upper gastrointestinal (UGI) tract Crohn's disease in adults compared to non‐UGI types
Babak Tamizifar, Peyman Adibi, Maryam Hadipour, Vahid Mohamadi
JGH Open.2023; 7(5): 325. CrossRef - Saudi Arabia consensus guidance for the diagnosis and management of adults with inflammatory bowel disease
Mahmoud H. Mosli, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Amr M. Khardaly, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baward
Saudi Journal of Gastroenterology.2023; 29(Suppl 1): S1. CrossRef - Gut inflammation induced by drugs: Can pathology help to differentiate from inflammatory bowel disease?
Naoimh Herlihy, Roger Feakins
United European Gastroenterology Journal.2022; 10(5): 451. CrossRef - Histopathologic Manifestations of Crohn Disease in Duodenal Endoscopy Biopsy: The Value of Different Patterns of Involvement of Brunner Glands
Badr AbdullGaffar, Hoda Quraishi
International Journal of Surgical Pathology.2021; 29(7): 710. CrossRef - “Is Focally Enhanced Active Inflammation of Brunner Glands a Sign of Crohn Duodenitis?”
Badr AbdullGaffar, Hoda Quraishi
International Journal of Surgical Pathology.2021; 29(8): 926. CrossRef - Systematic review with meta-analysis: The prevalence, risk factors and outcomes of upper gastrointestinal tract Crohn's disease
Yip Han Chin, Cheng Han Ng, Snow Yunni Lin, Sneha Rajiv Jain, Gwyneth Kong, Jeffery Wei Heng Koh, Darren Jun Hao Tan, David Eng Hui Ong, Mark Dhinesh Muthiah, Choon Seng Chong, Fung Joon Foo, Rupert Leong, Webber Pak Wo Chan
Digestive and Liver Disease.2021; 53(12): 1548. CrossRef - Non gastro-esophageal reflux disease related esophagitis: an overview with a histologic diagnostic approach
Luca Mastracci, Federica Grillo, Paola Parente, Elettra Unti, Serena Battista, Paola Spaggiari, Michela Campora, Luca Valle, Matteo Fassan, Roberto Fiocca
Pathologica.2020; 112(3): 128. CrossRef
- Focal Active Brunner Gland Lobulitis: Ignored or Yet Undetected Sign of Crohn Duodenitis?
- 8,062 View
- 170 Download
- 10 Web of Science
- 10 Crossref
- Inflammatory bowel diseases
- Risk Factors Associated with Impaired Ovarian Reserve in Young Women of Reproductive Age with Crohn’s Disease
- Yue Zhao, Baili Chen, Yao He, Shenghong Zhang, Yun Qiu, Rui Feng, Hongsheng Yang, Zhirong Zeng, Shomron Ben-Horin, Minhu Chen, Ren Mao
- Intest Res 2020;18(2):200-209. Published online March 31, 2020
- DOI: https://doi.org/10.5217/ir.2019.00103
-
Abstract
PDFPubReaderePub
- Background/Aims
Crohn’s disease (CD) primarily affects young female adults of reproductive age. Few studies have been conducted on this population’s ovarian reserve status. The aim of study was to investigate potential risk factors associated with low ovarian reserve, as reflected by serum anti-Müllerian hormone (AMH) in women of reproductive age with CD.
Methods
This was a case-control study. Cases included 87 patients with established CD, and healthy controls were matched by age, height and weight in a 1:1 ratio. Serum AMH levels were measured by enzyme-linked immunosorbent assay.
Results
The average serum AMH level was significantly lower in CD patients than in control group (2.47±2.08 ng/mL vs. 3.87±1.96 ng/mL, respectively, P<0.001). Serum AMH levels were comparable between CD patients and control group under 25 years of age (4.41±1.52 ng/mL vs. 3.49±2.10 ng/mL, P=0.06), however, serum AMH levels were significantly lower in CD patients over 25 years of age compared to control group (P<0.05). Multivariable analysis showed that an age greater than 25 (odds ratio [OR], 10.03; 95% confidence interval [CI], 1.90–52.93, P=0.007), active disease state (OR, 27.99; 95% CI, 6.13–127.95, P<0.001) and thalidomide use (OR, 15.66; 95% CI, 2.22–110.65, P=0.006) were independent risk factors associated with low ovarian reserve (serum AMH levels <2 ng/mL) in CD patients.
Conclusions
Ovarian reserve is impaired in young women of reproductive age with CD. Age over 25 and an active disease state were both independently associated with low ovarian reserve. Thalidomide use could result in impaired ovarian reserve. -
Citations
Citations to this article as recorded by- Inflammation and Ovarian Function in Reproductive‐Aged Women
Anneliese Long, Anne Z. Steiner, Amanda L. Thompson, Hannah R. Jahnke, Benjamin S. Harris, Anne Marie Jukic
American Journal of Human Biology.2025;[Epub] CrossRef - Chronic Intestinal Inflammation and Microbial Dysbiosis Are Associated With Female Reproductive Outcomes in a Mouse Model of Inflammatory Bowel Disease
Maria Martell, Clare F. Quarnstrom, Alexander Khoruts, Vaiva Vezys, Christopher Staley, Eugenia Shmidt
Gastro Hep Advances.2025; 4(7): 100670. CrossRef - Mendelian Randomization Analysis Reveals Causal Associations Between Autoimmune Diseases and Female Infertility Risk
Jinyuan Wang, Haojun Long, Mingxuan Su, Yichang Cao, Runtang Zhou, Xiang Li, Jiangming Li, Yuxia Tang, Jiayi Tang, Simin Wang, Linyue Tang, Ruxin Chen, Danqi Deng, Li Tang
Reproductive Toxicology.2025; : 108984. CrossRef - Efficacy and Tolerance of Thalidomide in Patients With Very Early Onset Inflammatory Bowel Disease
Matteo Bramuzzo, Fabiola Giudici, Serena Arrigo, Paolo Lionetti, Giovanna Zuin, Claudio Romano, Francesco Graziano, Simona Faraci, Patrizia Alvisi, Sara Signa, Luca Scarallo, Stefano Martelossi, Grazia Di Leo
Inflammatory Bowel Diseases.2024; 30(1): 20. CrossRef - Inhibin B and antiMüllerian hormone as surrogate markers of fertility in male and female Crohn’s disease patients: a case-control study
Ana Gutiérrez, Roser Muñoz-Pérez, Pedro Zapater, Cristina Mira, Andrés Rodríguez, Laura Sempere-Robles, María Eugenia Torregrosa, Rocio Alfayate, Violeta Moreno-Torres, Lorena Bernal, Olivia Belén-Galipienso, Jose Ignacio Cameo, Paula Sirera, Belen Herrer
Frontiers in Medicine.2024;[Epub] CrossRef - Factors associated with decreased ovarian reserve in Crohn's disease: A systematic review and meta‐analysis
Arthur Foulon, Nicolas Richard, Camille Guichard, Clara Yzet, Coraline Breuval, Jean Gondry, Rosalie Cabry‐Goubet, Audrey Michaud, Mathurin Fumery
Acta Obstetricia et Gynecologica Scandinavica.2024; 103(9): 1714. CrossRef - Serum anti-mullerian hormone, sex hormone, and nutrient levels in reproductive age women with celiac disease
Ailifeire Tuerxuntayi, Tian Shi, Beiyao Gao, Yan Feng, Ting Li, Wenjia Hui, Shenglong Xue, Feng Gao
Journal of Assisted Reproduction and Genetics.2024; 41(8): 2129. CrossRef - A Gender Perspective on Coloproctological Diseases: A Narrative Review on Female Disorders
Paola De Nardi, Greta Giacomel, Simone Orlandi, Giulia Poli, Mauro Pozzo, Marcella Rinaldi, Antonella Veglia, Renato Pietroletti
Journal of Clinical Medicine.2024; 13(20): 6136. CrossRef - Management strategies for inflammatory bowel disease before and during pregnancy
Xu-Jie Dai, Zhen Guo
World Chinese Journal of Digestology.2024; 32(11): 803. CrossRef - Inflammatory bowel disease can reduce ovarian reserve function in women: A systematic review and meta-analysis
Lin Guo, Yi Liu, Jiansheng Li, Quan Liu, Bing Liu, Xuewen Shi
Medicine.2023; 102(11): e33113. CrossRef - Inflammatory bowel disease in pregnancy and breastfeeding
Max N. Brondfield, Uma Mahadevan
Nature Reviews Gastroenterology & Hepatology.2023; 20(8): 504. CrossRef - Case report: A pregnant woman with Crohn disease who used ustekinumab to the 3rd trimester developed severe infection
Peng Guo, Wulan Cao
Medicine.2023; 102(48): e36253. CrossRef - Monitoring of Inflammatory Bowel Disease in Pregnancy: A Review of the Different Modalities
Reem Al-jabri, Panu Wetwittayakhlang, Peter L. Lakatos
Journal of Clinical Medicine.2023; 12(23): 7343. CrossRef - General review of pregnancy in inflammatory bowel disease
Elena Santos Pérez, Marta Calvo Moya
Revista Española de Enfermedades Digestivas.2022;[Epub] CrossRef - Inflammatory Bowel Disease and Reproductive Health: From Fertility to Pregnancy—A Narrative Review
Camilla Ronchetti, Federico Cirillo, Noemi Di Segni, Martina Cristodoro, Andrea Busnelli, Paolo Emanuele Levi-Setti
Nutrients.2022; 14(8): 1591. CrossRef - Ovarian reserve and IVF outcomes in patients with inflammatory bowel disease: A systematic review and meta-analysis
Honghao Sun, Jiao Jiao, Feng Tian, Qing Liu, Jiansu Bian, Rongmin Xu, Da Li, Xiuxia Wang, Hong Shu
eClinicalMedicine.2022; 50: 101517. CrossRef - Inflammatory Bowel Disease and Pregnancy
Eugenia Shmidt, Marla C. Dubinsky
American Journal of Gastroenterology.2022; 117(10S): 60. CrossRef - Reproductive Health in IBD Patients
Sanket Patel, Haleh Vaziri
Current Treatment Options in Gastroenterology.2021; 19(2): 237. CrossRef - Ovarian Reserve Assessed by the Anti-Mullerian Hormone and Reproductive Health Parameters in Women With Crohn´s Disease, a Case-Control Study
T. Koller, J. Kollerová, T. Hlavatý, B. Kadlečková, J. Payer
Physiological Research.2021; : S69. CrossRef - THE ROLE OF IMMUNOGLOBULIN A IN THE INFLAMMATORY PROCESS INVOLVING NEUTROPHILS
O.O. Prudnikov, I.M. Prudnikov, V.M. Tsyvkin, A.M. Smirnov, R.I. Yanchiy
Fiziolohichnyĭ zhurnal.2021; 67(5): 44. CrossRef - Update on Pregnancy in Patients with IBD
Rachel W. Winter, Sonia Friedman
Current Treatment Options in Gastroenterology.2020; 18(3): 423. CrossRef
- Inflammation and Ovarian Function in Reproductive‐Aged Women
- 7,658 View
- 133 Download
- 17 Web of Science
- 21 Crossref
- Inflammatory bowel diseases
- Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey
- Sun-Ho Lee, Kiju Chang, Ki Seok Seo, Yun Kyung Cho, Eun Mi Song, Sung Wook Hwang, Dong-Hoon Yang, Byong Duk Ye, Jeong-Sik Byeon, Seung-Jae Myung, Suk-Kyun Yang, Sang Hyoung Park
- Intest Res 2020;18(2):192-199. Published online April 3, 2020
- DOI: https://doi.org/10.5217/ir.2019.00115
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
The use of complementary and alternative medicine (CAM) is a global phenomenon, including inflammatory bowel disease (IBD) patients. We aimed to assess the change in prevalence and patterns of CAM use, and attitudes towards CAM over an 8-year time interval (2006 vs. 2014) among IBD patients in Korea.
Methods
A total of 221 IBD patients (CD=142, UC=79) were asked to complete a questionnaire regarding CAM at two time points: at enrollment (2006) and 8 years later (2014/2015).
Results
The proportion of patients ever using CAM increased significantly from 60.2% in 2006 to 79.6% in 2014 (P<0.001), while the proportion of current CAM users increased slightly (35.7% to 38.0%, P=0.635); 21.7% used CAM consistently at both time points. The proportion of patients who felt CAM was less effective (P<0.001) and more expensive (P=0.04) than conventional treatments increased over time. Also, the proportion among ever CAM users who perceived a positive effect from CAM significantly decreased in 2014 compared to 2006 (P=0.004). Higher education (adjusted odds ratio [aOR], 2.10), prior side effects to conventional therapies (aOR, 2.23), and prior use of corticosteroids (aOR, 2.51) were associated with CAM use. Interestingly, use of CAM before IBD diagnosis (aOR, 2.73) was significantly associated with consistent CAM use.
Conclusions
Although the attitudes toward CAM have become less favorable, the majority of IBD patients have experienced CAM with an overall increase of current CAM users over time. Moreover, more than half of current CAM users used CAM consistently over time. -
Citations
Citations to this article as recorded by- Effects of self-acupressure on quality of life and abdominal pain severity among patients with inflammatory bowel disease: A randomized sham-controlled trial
Nahid Rajai, Zahra Abbasi, Amir Hosein Pishgooie, Fatemeh Teymouri, Mohammad Imanipour
Journal of Ayurveda and Integrative Medicine.2025; 16(2): 101080. CrossRef - Use of Complementary and Alternative Medicine by Greek Patients with Inflammatory Bowel Disease
John Triantafillidis, Aristofanis Gikas, Georgia Kontrarou, Manousos Konstantoulakis, Apostolos Papalois
Nutrients.2024; 16(21): 3679. CrossRef - A comparative analysis of complementary therapies use among patients attending diabetic clinics in Taiwan: 2007 vs. 2023
Hsiao-Yun Chang, Yu-Yao Huang, Chin-Jung Chung, Feng-Hsuan Liu
BMC Complementary Medicine and Therapies.2023;[Epub] CrossRef - Perspectives of East Asian patients and physicians on complementary and alternative medicine use for inflammatory bowel disease: results of a cross-sectional, multinational study
Eun Soo Kim, Chung Hyun Tae, Sung-Ae Jung, Dong Il Park, Jong Pil Im, Chang Soo Eun, Hyuk Yoon, Byung Ik Jang, Haruhiko Ogata, Kayoko Fukuhara, Fumihito Hirai, Kazuo Ohtsuka, Jing Liu, Qian Cao
Intestinal Research.2022; 20(2): 192. CrossRef - Improvement in Medication Adherence after Pharmacist Intervention Is Associated with Favorable Clinical Outcomes in Patients with Ulcerative Colitis
Jae Song Kim, Min Jung Geum, Eun Sun Son, Yun Mi Yu, Jae Hee Cheon, Kyeng Hee Kwon
Gut and Liver.2022; 16(5): 736. CrossRef - Comprehensive study on the administrative, economic, regional, and regulatory prospects of complementary and alternative medicine (CAM) in inflammatory bowel disease (IBD)
Taraneh Mousavi, Shekoufeh Nikfar, Mohammad Abdollahi
Expert Review of Clinical Pharmacology.2021; 14(7): 865. CrossRef - Complementary and alternative medicine in patients with inflammatory bowel disease: hype or evidence?
Jae Myung Cha
Intestinal Research.2020; 18(2): 141. CrossRef
- Effects of self-acupressure on quality of life and abdominal pain severity among patients with inflammatory bowel disease: A randomized sham-controlled trial
- 6,446 View
- 123 Download
- 7 Web of Science
- 7 Crossref
- Inflammatory bowel diseases
- Exclusive enteral nutrition for induction of remission in anti-tumor necrosis factor refractory adult Crohn’s disease: the Indian experience
- Ajit Sood, Arshdeep Singh, Ritu Sudhakar, Vandana Midha, Ramit Mahajan, Varun Mehta, Yogesh Kumar Gupta, Kirandeep Kaur
- Intest Res 2020;18(2):184-191. Published online February 25, 2020
- DOI: https://doi.org/10.5217/ir.2019.00094
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Exclusive enteral nutrition (EEN) is recommended for induction of remission in pediatric Crohn’s disease (CD). However, it is not currently recommended for inducing remission in adults. This report describes the use of 12-week EEN for induction of remission in anti-tumor necrosis factor (anti-TNF) refractory adult CD.
Methods
This is a retrospective analysis of adults with moderate to severe active (Crohn’s Disease Activity Index [CDAI] >220) anti-TNF refractory CD, who received EEN for 12 weeks between April 2018 and March 2019 at Dayanand Medical College and Hospital, Ludhiana, India. Primary outcomes included achievement of clinical remission and fistula healing at 12 weeks. Improvement in inflammatory markers and nutritional status were the secondary end points.
Results
Out of 23 patients who received anti-TNF agents, 7 (30.4%) were refractory and were offered EEN as a salvage therapy. Six patients (66.7% females, mean age 25.6±6.5 years) consented. Four patients (66.6%) achieved clinical remission (CDAI <150). Mean CDAI of patients decreased significantly after 12 weeks of EEN (388.8±74.8 vs. 160.0±25.2, P<0.001). Perianal fistulas showed clinical response (drainage decreased by >50%), though none achieved remission. Entero-enteric fistulae showed complete healing. Mean body mass index improved from 15.6±3.1 to 18.9±1.9 kg/m2 at week 12 (P=0.003). Hemoglobin and serum albumin also improved from 8.2±1.1 g/dL and 2.8±0.3 g/dL at baseline to 12.6±0.6 g/dL and 3.6±0.5 g/dL post-EEN respectively (P<0.001 and P=0.006 respectively).
Conclusions
EEN appears to be an effective and well tolerated therapy for induction of remission in anti-TNF refractory adult CD. More data from prospective trials with larger number of patients is required. -
Citations
Citations to this article as recorded by- Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use
Hellen Kuo, Katrina Tognolini, Rumbidzai Mutsekwa, Dheeraj Shukla, Laura Willmann, Hadi Moattar, Alexander Dorrington, Naveed Ishaq, Maneesha Bhullar, John Edwards, Waled Mohsen, Pradeep Kakkadasam Ramaswamy
Frontline Gastroenterology.2025; 16(1): 3. CrossRef - Enteral Nutrition in Crohn’s Disease: A Comprehensive Review of Its Role in Induction and Maintenance of Remission and Perioperative Management in Adult Patients
André Bargas, Carolina Palmela, Luisa Glória
Nutrients.2025; 17(9): 1481. CrossRef - Management of Perianal Fistulizing Crohn’s Disease
Arshdeep Singh, Vandana Midha, Gursimran Singh Kochhar, Bo Shen, Ajit Sood
Inflammatory Bowel Diseases.2024; 30(9): 1579. CrossRef - Pharmacogenetics in personalized treatment in pediatric patients with inflammatory bowel disease (IBD)
Daniela Kosorínová, Pavlína Suchá, Zuzana Havlíčeková, Marek Pršo, Pavol Dvoran, Peter Bánovčin
Česko-slovenská pediatrie.2024; 79(4): 213. CrossRef - Clinical and magnetic resonance imaging spectrum of complex perianal fistulizing Crohn’s disease: A cohort study from northern India
Arshdeep Singh, Chandan Kakkar, Shreya Garg, Kirti Arora, Vandana Midha, Ramit Mahajan, Satpal Singh Virk, Narender Pal Jain, Dharmatma Singh, Kriti Sood, Ashish Tripathi, Dhruv Gupta, Ishita Gupta Kaushal, Ritu Dhawan Galhotra, Kavita Saggar, Ajit Sood
Indian Journal of Gastroenterology.2023; 42(5): 668. CrossRef - Use of oral diet and nutrition support in management of stricturing and fistulizing Crohn's disease
Kush Fansiwala, Neha D. Shah, Kelly A. McNulty, Mary R. Kwaan, Berkeley N. Limketkai
Nutrition in Clinical Practice.2023; 38(6): 1282. CrossRef - Incidence and Prevalence of Inflammatory Bowel Disease across Asia
Jihye Park, Jae Hee Cheon
Yonsei Medical Journal.2021; 62(2): 99. CrossRef - Review of exclusive enteral therapy in adult Crohn’s disease
Nikola Mitrev, Hin Huang, Barbara Hannah, Viraj Chandana Kariyawasam
BMJ Open Gastroenterology.2021; 8(1): e000745. CrossRef - Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef - Enteral nutrition in the biologic era: learn from yesterday, live for today, hope for tomorrow
Tadakazu Hisamatsu
Intestinal Research.2020; 18(2): 139. CrossRef
- Adjunct polymeric exclusive enteral nutrition helps achieve biochemical remission in active Crohn’s disease in adults irrespective of disease location and concomitant corticosteroid use
- 8,135 View
- 187 Download
- 11 Web of Science
- 10 Crossref
- Miscellaneous
- Vegetarianism as a protective factor for asymptomatic colonic diverticulosis in Asians: a retrospective cross-sectional and case-control study
- Jihun Bong, Hyoun Woo Kang, Hyeki Cho, Ji Hyung Nam, Dong Kee Jang, Jae Hak Kim, Jun Kyu Lee, Yun Jeong Lim, Moon-Soo Koh, Jin Ho Lee
- Intest Res 2020;18(1):121-129. Published online November 1, 2019
- DOI: https://doi.org/10.5217/ir.2019.00106
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Dietary fiber intake is considered a protective factor for diverticular disease such as diverticulitis. However, evidence for an inverse connection between dietary fiber consumption and asymptomatic colonic diverticulosis is lacking. Specifically, few studies have investigated this subject in Asians with different presentations of diverticulosis. Therefore, we assessed the protective effects of a vegetarian diet for asymptomatic colonic diverticulosis in Buddhist monks who are obligatory vegetarians for spiritual reasons compared with the general population.
Methods
A retrospective, cross-sectional, case-control study was conducted in age- and sex-matched Buddhist monks and the general population who underwent colonoscopy for screening at a Korean health promotion center from August 2005 to June 2018. We compared the prevalence of asymptomatic diverticulosis between the 2 groups using a self-administered questionnaire.
Results
In this study, a total of 1,316 individuals were included (Buddhist monks of 658 and general population of 658) with a mean age of 52.6±9.5 years. The prevalence of asymptomatic diverticulosis in Buddhist monks was lower compared with the general population (6.7% [44/658] vs. 10.8% [71/658], P=0.008). Buddhist monks had a higher rate of high body mass index (BMI) and metabolic syndrome. By a multivariate regression analysis model, a nonvegetarian diet (odds ratio [OR], 1.82; 95% confidence interval [CI], 1.21–2.72, P=0.004), old age (OR, 4.53; 95% CI, 1.36–15.12; P=0.014), male sex (OR, 1.91; 95% CI, 1.28–2.85; P=0.002), and a high BMI (OR, 1.50; 95% CI, 1.01–2.23; P=0.047) were independent predictors of asymptomatic diverticulosis. Moreover, a nonvegetarian diet was associated with both right-sided and left-sided diverticulosis.
Conclusions
A nonvegetarian diet may increase a risk of asymptomatic colonic diverticulosis in Asians. -
Citations
Citations to this article as recorded by- Association of Metabolic Syndrome Components and Colonic Diverticulosis in the Very Elderly: A Tertiary Health Network Study
Hammad Liaquat, Farah Harmouch, Nishit Patel, Zarian Prenatt, Jill Stoltzfus, Berhanu Geme, Noel Martins, Kimberly Chaput
Cureus.2024;[Epub] CrossRef - Not all acute colonic diverticulitis follows the same course: a potential risk for immunocompromised individuals
Yehyun Park
Intestinal Research.2023; 21(4): 415. CrossRef - Age, alcohol, sex, and metabolic factors as risk factors for colonic diverticulosis
Ye Yan, Jian-Sheng Wu, Shuang Pan
World Journal of Clinical Cases.2022; 10(1): 136. CrossRef - Diagnosis and Treatment of Colonic Diverticular Disease
You Sun Kim
The Korean Journal of Gastroenterology.2022; 79(6): 233. CrossRef - The prevalence of right‐sided colonic diverticulosis in a New Zealand population
Greg A. Turner, Michael J. O'Grady, Sajith C. Senadeera, Chris J. Wakeman, Andrew McCombie, Rachel V. Purcell, Frank A. Frizelle
ANZ Journal of Surgery.2021; 91(10): 2110. CrossRef - The Epidemiology and Etiology of Right-Sided Colonic Diverticulosis: A Review
Greg A. Turner, Michael J. O’Grady, Rachel V. Purcell, Frank A. Frizelle
Annals of Coloproctology.2021; 37(4): 196. CrossRef
- Association of Metabolic Syndrome Components and Colonic Diverticulosis in the Very Elderly: A Tertiary Health Network Study
- 7,966 View
- 238 Download
- 6 Web of Science
- 6 Crossref
- Functional bowel disorder
- Proinflammatory cytokines in irritable bowel syndrome: a comparison with inflammatory bowel disease
- Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, Stamatis S Papadatos, Konstantinos Katsanos, Vasiliki Galani
- Intest Res 2020;18(1):115-120. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00125
-
Abstract
PDFPubReaderePub
- Background/Aims
Irritable bowel syndrome (IBS) is a common disease often considered as a functional intestinal disorder. Inflammation in IBS is a quite intriguing theory. The aim of this study was to investigate tumor necrosis factor (TNF)-α, interleukin (IL)-1β and IL-6 expression in inflammatory bowel disease (IBD) patients, IBS patients and normal controls.
Methods
IBS and IBD patients along with normal controls were recruited in the study. In all groups, 2 pinch biopsies were taken at each of 3 anatomical sites (terminal ileum, cecum, and rectum). IBS patients were also subcategorized according to the syndrome clinical manifestations. Two monoclonal antibodies (mAb), TNF-α mAb and IL-6 mAb, and one polyclonal antibody IL-1β mAb were applied for immunohistochemical analysis.
Results
In IBD patients intensity of TNF-α and IL-1β were lower than in IBS patients or controls, while IL-6 was significantly increased comparing to the aforementioned groups. In IBS patients TNF-α was increased comparing to IBD patients or controls, while IL-6 and IL-1β were similar to controls. In IBS subgroups, TNF-α was lower in diarrhea predominant IBS patients and higher constipation predominant IBS patients. Differences among IBS subgroups regarding IL-6 and IL-1β were nonsignificant.
Conclusions
IL-6 seems to be the most important proinflammatory cytokine in IBD patients, while TNF-α could play a more significant role in IBS pathogenesis. -
Citations
Citations to this article as recorded by- Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms
Yutaka Nakagawa, Shizuo Yamada
Molecular and Cellular Biochemistry.2025; 480(5): 2661. CrossRef - The Role of Bacteria-Derived Hydrogen Sulfide in Multiple Axes of Disease
Aleksandr Birg, Henry C. Lin
International Journal of Molecular Sciences.2025; 26(7): 3340. CrossRef - Guardians at the Gate: Immune System in Gastrointestinal Diseases
Elena Layunta, Jose Emilio Mesonero, Eva Latorre
International Journal of Molecular Sciences.2024; 25(11): 5933. CrossRef - Novel Dairy Fermentates Have Differential Effects on Key Immune Responses Associated with Viral Immunity and Inflammation in Dendritic Cells
Dearbhla Finnegan, Claire Connolly, Monica A. Mechoud, Jamie A. FitzGerald, Tom Beresford, Harsh Mathur, Lorraine Brennan, Paul D. Cotter, Christine E. Loscher
Foods.2024; 13(15): 2392. CrossRef - The Latest Data Concerning the Etiology and Pathogenesis of Irritable Bowel Syndrome
Vlad Alexandru Ionescu, Gina Gheorghe, Teodor Florin Georgescu, Nicolae Bacalbasa, Florentina Gheorghe, Camelia Cristina Diaconu
Journal of Clinical Medicine.2024; 13(17): 5124. CrossRef - Morphological Changes of the Pituitary Gland in Patients with Irritable Bowel Syndrome Using Magnetic Resonance Imaging
Jessica Abou Chaaya, Jennifer Abou Chaaya, Batoul Jaafar, Lea Saab, Jad Abou Chaaya, Elie Al Ahmar, Elias Estephan
Journal of Imaging.2024; 10(9): 226. CrossRef - Review article: The role of the gut–brain axis in inflammatory bowel disease and its therapeutic implications
Christy Riggott, Alexander C. Ford, David J. Gracie
Alimentary Pharmacology & Therapeutics.2024; 60(9): 1200. CrossRef - Unraveling the intricacies of neutrophil extracellular traps in inflammatory bowel disease: Pathways, biomarkers, and promising therapies
Yilin Wu, Jun Shen
Cytokine & Growth Factor Reviews.2024; 80: 156. CrossRef - Transcriptional Responses of Lacticaseibacillus rhamnosus to TNFα, IL-6, IL-8, and IL-10 Cytokines
Ksenia M. Klimina, Marina S. Dyachkova, Vladimir A. Veselovsky, Natalia V. Zakharevich, Aleksandra A. Strokach, Oksana V. Selezneva, Egor A. Shitikov, Dmitry A. Bespiatykh, Roman A. Yunes, Elena U. Poluektova, Maya V. Odorskaya, Polina S. Ostroukhova, Ser
Biology.2024; 13(11): 931. CrossRef - Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites
María José García Mansilla, María Jesús Rodríguez Sojo, Andrea Roxana Lista, Ciskey Vanessa Ayala Mosqueda, Antonio Jesús Ruiz Malagón, Julio Gálvez, Alba Rodríguez Nogales, María José Rodríguez Sánchez
Nutrients.2024; 17(1): 155. CrossRef - Evaluation of two laboratory model methods for diarrheal irritable bowel syndrome
Qian Chen, Hua Zhang, Chang-Yue Sun, Qing-Ying He, Rui-Rong Zhang, Bin-Fei Luo, Zi-Hao Zhou, Xiao-Fan Chen
Molecular Medicine.2023;[Epub] CrossRef - Structural properties and anti-inflammatory activity of purified polysaccharides from Hen-of-the-woods mushrooms (Grifola frondosa)
Xiaoyi Liu, Shuai Chen, Huijuan Liu, Jiao Xie, K. M. Faridul Hasan, Qibing Zeng, Shaofeng Wei, Peng Luo
Frontiers in Nutrition.2023;[Epub] CrossRef - An Asian perspective on irritable bowel syndrome
Kee Wook Jung, Seung-Jae Myung
Intestinal Research.2023; 21(2): 189. CrossRef - Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik
Molecules.2023; 28(13): 5081. CrossRef - Structure and Metabolic Activity of the Gut Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome Combined with Functional Dyspepsia
Aleksandra Kovaleva, Elena Poluektova, Roman Maslennikov, Oxana Zolnikova, Oleg Shifrin, Anna Kudryavtseva, George Krasnov, Maria Fedorova, Anna Karchevskaya, Vladimir Ivashkin
Gastrointestinal Disorders.2023; 5(3): 296. CrossRef - NK cells vs. obesity: A tale of dysfunction & redemption
Conor De Barra, Donal O'Shea, Andrew E. Hogan
Clinical Immunology.2023; 255: 109744. CrossRef - Non-invasive neuromodulation: an emerging intervention for visceral pain in gastrointestinal disorders
Md Jahangir Alam, Jiande D. Z. Chen
Bioelectronic Medicine.2023;[Epub] CrossRef - Gut–Brain Axis, Microbiota and Probiotics—Current Knowledge on Their Role in Irritable Bowel Syndrome: A Review
Cristina Maria Marginean, Mihaela Popescu, Andrei Ioan Drocas, Sergiu Marian Cazacu, Radu Mitrut, Iulia Cristina Marginean, George Alexandru Iacob, Marian Sorin Popescu, Anca Oana Docea, Paul Mitrut
Gastrointestinal Disorders.2023; 5(4): 517. CrossRef - Comparative treatment of Sulfasalazine+Ezetimibe combination and Sulfasalazine in a rat model with induced colitis
Farrah Rasool Jaafar, Ahmed Abu-Raghif
Journal of Medicine and Life.2023; 16(8): 1165. CrossRef - Screening and Evaluation of Probiotics for Reducing Intestinal Inflammation
雅君 陈
Hans Journal of Food and Nutrition Science.2022; 11(01): 44. CrossRef - Protection against ulcerative colitis and colorectal cancer by evodiamine via anti‑inflammatory effects
Yongfeng Zhang, Yaqin Zhang, Yang Zhao, Wanyue Wu, Weiqi Meng, Yulin Zhou, Ye Qiu, Chenliang Li
Molecular Medicine Reports.2022;[Epub] CrossRef - The Role of Neuro-Immune Interaction in Chronic Pain Conditions; Functional Somatic Syndrome, Neurogenic Inflammation, and Peripheral Neuropathy
Elaine Meade, Mary Garvey
International Journal of Molecular Sciences.2022; 23(15): 8574. CrossRef - Ameliorating effects of electroacupuncture on the low‐grade intestinal inflammation in rat model of diarrhea‐predominant irritable bowel syndrome
Xuemei Li, Kuiyu Ren, Xiaojuan Hong, Sha Guo, Shuguang Yu, Sha Yang
Journal of Gastroenterology and Hepatology.2022; 37(10): 1963. CrossRef - Healthy Sleep Every Day Keeps the Doctor Away
Cailan Lindsay Feingold, Abbas Smiley
International Journal of Environmental Research and Public Health.2022; 19(17): 10740. CrossRef - Compositional Changes in the Gut Microbiota of Responders and Non-responders to Probiotic Treatment Among Patients With Diarrhea-predominant Irritable Bowel Syndrome: A Post Hoc Analysis of a Randomized Clinical Trial
Seung Yong Shin, Sein Park, Jung Min Moon, Kisung Kim, Jeong Wook Kim, Jongsik Chun, Tae Hee Lee, Chang Hwan Choi
Journal of Neurogastroenterology and Motility.2022; 28(4): 642. CrossRef - Overlap of Functional Gastrointestinal Disorders: Common Mechanisms of Pathogenesis as a Key to Rational Therapy
S. N. Mekhdiyev, O. A. Mekhdieva, O. M. Berko
Russian Journal of Gastroenterology, Hepatology, Coloproctology.2022; 32(4): 95. CrossRef - Effect of Heat-Killed Lactobacillus casei DKGF7 on a Rat Model of Irritable Bowel Syndrome
Gyeol Seong, Seungbaek Lee, Yang Won Min, Yeon Sil Jang, Hong Seog Kim, Eui-Joong Kim, So-Young Park, Cheol-Hyun Kim, Dong Kyung Chang
Nutrients.2021; 13(2): 568. CrossRef - A Comprehensive Review: Sphingolipid Metabolism and Implications of Disruption in Sphingolipid Homeostasis
Brianna M. Quinville, Natalie M. Deschenes, Alex E. Ryckman, Jagdeep S. Walia
International Journal of Molecular Sciences.2021; 22(11): 5793. CrossRef - Lactiplantibacillus plantarum 299v (LP299V®): three decades of research
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson, N. Larsson
Beneficial Microbes.2021; 12(5): 441. CrossRef - Immunohistochemical Study of Adhesion Molecules in Irritable Bowel Syndrome
Antigony Mitselou, Vasileios Grammeniatis, Anna Varouktsi, Stamatis S. Papadatos, Antonios Klaroudas, Konstantinos Katsanos, Vasiliki Galani
Advanced Biomedical Research.2021; 10(1): 21. CrossRef - TNF-α, IL-17, and IL-22 production in the rectal mucosa of nonceliac wheat sensitivity patients: role of adaptive immunity
Pasquale Mansueto, Diana Di Liberto, Francesca Fayer, Maurizio Soresi, Girolamo Geraci, Antonio Giulio Giannone, Aurelio Seidita, Alberto D’Alcamo, Francesco La Blasca, Marianna Lo Pizzo, Ada Maria Florena, Francesco Dieli, Antonio Carroccio
American Journal of Physiology-Gastrointestinal and Liver Physiology.2020; 319(3): G281. CrossRef - Sudachinoid- and Ichangensin-Type Limonoids from Citrus junos Downregulate Pro-Inflammatory Cytokines
Jihun Shin, Hwa Young Song, Mina Lee
International Journal of Molecular Sciences.2020; 21(18): 6963. CrossRef - Differential clusterization of soluble and extracellular vesicle-associated cytokines in myocardial infarction
Anna Lebedeva, Wendy Fitzgerald, Ivan Molodtsov, Alexander Shpektor, Elena Vasilieva, Leonid Margolis
Scientific Reports.2020;[Epub] CrossRef - Lactoferrin in the Prevention and Treatment of Intestinal Inflammatory Pathologies Associated with Colorectal Cancer Development
Antimo Cutone, Giusi Ianiro, Maria Stefania Lepanto, Luigi Rosa, Piera Valenti, Maria Carmela Bonaccorsi di Patti, Giovanni Musci
Cancers.2020; 12(12): 3806. CrossRef
- Novel hypothesis and therapeutic interventions for irritable bowel syndrome: interplay between metal dyshomeostasis, gastrointestinal dysfunction, and neuropsychiatric symptoms
- 8,096 View
- 201 Download
- 35 Web of Science
- 34 Crossref
- Colorectal neoplasia
- Microvascular density under magnifying narrow-band imaging endoscopy in colorectal epithelial neoplasms
- Takahiro Gonai, Keisuke Kawasaki, Shotaro Nakamura, Shunichi Yanai, Risaburo Akasaka, Kunihiko Sato, Yousuke Toya, Kensuke Asakura, Jun Urushikubo, Yasuko Fujita, Makoto Eizuka, Noriyuki Uesugi, Tamotsu Sugai, Takayuki Matsumoto
- Intest Res 2020;18(1):107-114. Published online November 4, 2019
- DOI: https://doi.org/10.5217/ir.2019.00061
-
Abstract
PDFPubReaderePub
- Background/Aims
Magnifying endoscopic classification systems, such as the Japan narrow-band imaging (NBI) Expert Team (JNET) classification, have been widely used for predicting the histologic diagnosis and invasion depth of colorectal epithelial tumors. However, disagreement exists among observers regarding magnifying endoscopic diagnosis, because these classification systems are subjective. We herein investigated the utility of endoscopic microvascular density (eMVD) calculated from magnifying NBI endoscopic images in colorectal tumors.
Methods
We reviewed magnifying NBI endoscopic images from 169 colorectal epithelial tumors (97 adenomas, 72 carcinomas/high-grade dysplasias) resected endoscopically or surgically. The eMVD on magnifying NBI endoscopic images was evaluated using image-editing software, and relationships between eMVD and clinical, endoscopic, and pathological findings were retrospectively analyzed.
Results
The eMVD in carcinomas (0.152 ± 0.079) was significantly higher than that in adenomas (0.119 ± 0.059, P< 0.05). The best cutoff value for distinguishing carcinoma from adenoma was 0.133. Sensitivity, specificity, and accuracy were 56.9%, 67.0%, and 62.7%, respectively. In addition, JNET type 2B tumors showed significantly higher eMVD (0.162 ± 0.079) compared to type 2A tumors (0.111 ± 0.050, P< 0.05).
Conclusions
The eMVD as determined by magnifying NBI endoscopy is considered to be a possible objective indicator for differentiating colorectal carcinomas from adenomas. -
Citations
Citations to this article as recorded by- Novel physiological analysis using blood flow velocity for colonic polyps: Pilot study
Eiji Kamba, Takashi Murakami, Naoki Tsugawa, Kei Nomura, Keiichi Haga, Yoichi Akazawa, Hirofumi Fukushima, Hiroya Ueyama, Kenshi Matsumoto, Tomoyoshi Shibuya, Takeshi Terai, Takashi Yao, Akihito Nagahara
Endoscopy International Open.2024; 12(06): E781. CrossRef - Feasibility of moxifloxacin and proflavine dual fluorescence imaging for detecting gastrointestinal neoplastic lesions: A prospective study
Kwangwoo Nam, Noseong Park, Seunghun Lee, Suil Jeon, Jungbin Lee, Seung‐Mo Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Byong Duk Ye, Jeong‐Sik Byeon, Suk‐Kyun Yang, Jeong Hoon Lee, Do Hoon Kim, Ki Hean Kim, Seung‐Jae Myung
Lasers in Surgery and Medicine.2023; 55(4): 378. CrossRef - Application of artificial intelligence in diagnosis and treatment of colorectal cancer: A novel Prospect
Zugang Yin, Chenhui Yao, Limin Zhang, Shaohua Qi
Frontiers in Medicine.2023;[Epub] CrossRef - Chicken skin mucosa surrounding small colorectal cancer could be an endoscopic predictive marker of submucosal invasion
Ying-Jie Zhang, Wu Wen, Fan Li, Yi Jian, Chuan-Ming Zhang, Meng-Xia Yuan, Ye Yang, Feng-Lin Chen
World Journal of Gastrointestinal Oncology.2023; 15(6): 1062. CrossRef - A review on self-healing featured soft robotics
Md. Ariful Islam, Labanya Talukder, Md. Firoj Al, Subrata K. Sarker, S. M. Muyeen, Prangon Das, Md. Mehedi Hasan, Sajal K. Das, Md. Manirul Islam, Md. Robiul Islam, Sumaya Ishrat Moyeen, Faisal R. Badal, Md. Hafiz Ahamed, Sarafat Hussain Abhi
Frontiers in Robotics and AI.2023;[Epub] CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intestinal Research.2022; 20(3): 281. CrossRef - Colonic Chicken Skin Mucosa Surrounding Colon Polyps Is an Endoscopic Predictive Marker for Colonic Neoplastic Polyps
Yu Mi Lee, Kyung Ho Song, Hoon Sup Koo, Choong-Sik Lee, Inseok Ko, Sang Hyuk Lee, Kyu Chan Huh
Gut and Liver.2022; 16(5): 754. CrossRef - Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef - Response to Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Istvan Racz, Andras Horvath, Zoltán Horvath
Clinical Endoscopy.2022; 55(5): 701. CrossRef - Photoacoustic endoscopy: A progress review
Heng Guo, Ying Li, Weizhi Qi, Lei Xi
Journal of Biophotonics.2020;[Epub] CrossRef - Diagnostic efficacy of the Japan Narrow-band-imaging Expert Team and Pit pattern classifications for colorectal lesions: A meta-analysis
Yu Zhang, Hui-Yan Chen, Xiao-Lu Zhou, Wen-Sheng Pan, Xin-Xin Zhou, Hang-Hai Pan
World Journal of Gastroenterology.2020; 26(40): 6279. CrossRef
- Novel physiological analysis using blood flow velocity for colonic polyps: Pilot study
- 7,491 View
- 119 Download
- 11 Web of Science
- 12 Crossref
- Colorectal neoplasia
- Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery
- Yun Sik Choi, Wan Soo Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Jeong-Sik Byeon
- Intest Res 2020;18(1):96-106. Published online January 30, 2020
- DOI: https://doi.org/10.5217/ir.2019.00092
-
Abstract
PDFPubReaderePub
- Background/Aims
We aimed to investigate the proportion of and risk factors for residual cancer and/or lymph node metastasis after surgery was performed because of high-risk pathological features in endoscopic resection specimen of suspected superficial submucosal colorectal cancer (SSMC).
Methods
We reviewed medical records of 497 patients (58.8 ± 9.8 years, 331 males) undergoing endoscopic resection of suspected SSMC. High-risk pathological features included: deep submucosal cancer invasion ≥ 1,000 μm; positive lymphovascular and/or perineural invasion; poorly differentiated adenocarcinoma; and positive resection margin. We investigated the occurrence of additional surgery and residual cancer and/or lymph node involvement in the surgical specimen.
Results
En bloc resection was performed in 447 patients (89.9%). High-risk pathological features were detected in 372 patients (74.8%). Additional surgery was performed in 336 of 372 patients with high-risk pathological features. Of these, 47 surgical specimens (14.0%) showed residual cancer and/or lymph node metastasis. Piecemeal resection was more common in those with residual cancer and/or lymph node involvement than those without (9/47 [19.1%] vs. 24/289 [8.3%], P= 0.032). Positive resection margin was also significantly associated with positive residual cancer and/or lymph node involvement. As the number of high-risk pathological features increased, the risk of regional lymph node metastasis increased proportionally (P= 0.002).
Conclusions
High-risk pathological features were frequently detected after endoscopic resection of suspected SSMC while residual cancer and/or lymph node metastasis were not commonly present in the additional surgical specimen. Further optimized strategy for proper endoscopic management of suspected SSMC is necessary. -
Citations
Citations to this article as recorded by- Artificial Intelligence Models May Aid in Predicting Lymph Node Metastasis in Patients with T1 Colorectal Cancer
Ji Eun Baek, Hahn Yi, Seung Wook Hong, Subin Song, Ji Young Lee, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Namkug Kim, Jeong-Sik Byeon
Gut and Liver.2025; 19(1): 69. CrossRef - Artificial Intelligence in Lymph Node Metastasis Prediction for T1 Colorectal Cancer: Promise and Challenges
Jung Ho Bae
Gut and Liver.2025; 19(1): 3. CrossRef - Survey of the Actual Practices Used for Endoscopic Removal of Colon Polyps in Korea: A Comparison with the Current Guidelines
Jeongseok Kim, Tae-Geun Gweon, Min Seob Kwak, Su Young Kim, Seong Jung Kim, Hyun Gun Kim, Sung Noh Hong, Eun Sun Kim, Chang Mo Moon, Dae Seong Myung, Dong-Hoon Baek, Shin Ju Oh, Hyun Jung Lee, Ji Young Lee, Yunho Jung, Jaeyoung Chun, Dong-Hoon Yang, Eun R
Gut and Liver.2025; 19(1): 77. CrossRef - Salvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer – a nationwide cross-sectional cohort study
L.R. Moolenaar, E.G.M. van Geffen, S.J.A. Hazen, T.C. Sluckin, G.L. Beets, J.W.A. Leijtens, A.K. Talsma, J.H.W. de Wilt, P.J. Tanis, M. Kusters, R. Hompes, J.B. Tuynman, Arend G.J. Aalbers, Susanna M. van Aalten, Femke J. Amelung, Marjolein Ankersmit, Imo
European Journal of Surgical Oncology.2025; : 109623. CrossRef - Survival machine learning model of T1 colorectal postoperative recurrence after endoscopic resection and surgical operation: a retrospective cohort study
Zhihong Li, Yiliyaer Aihemaiti, Qianqian Yang, Yiliminuer Ahemai, Zimei Li, Qianqian Du, Yan Wang, Hanxiang Zhang, Yingbin Cai
BMC Cancer.2025;[Epub] CrossRef - Curative criteria for endoscopic treatment of colorectal cancer
Lucille Quénéhervé, Mathieu Pioche, Jérémie Jacques
Best Practice & Research Clinical Gastroenterology.2024; 68: 101883. CrossRef - Early Rectal Cancer and Local Excision: A Narrative Review
Cecilia Binda, Matteo Secco, Luigi Tuccillo, Chiara Coluccio, Elisa Liverani, Carlo Felix Maria Jung, Carlo Fabbri, Giulia Gibiino
Journal of Clinical Medicine.2024; 13(8): 2292. CrossRef - Prediction of Lymph Node Metastasis in T1 Colorectal Cancer Using Artificial Intelligence with Hematoxylin and Eosin-Stained Whole-Slide-Images of Endoscopic and Surgical Resection Specimens
Joo Hye Song, Eun Ran Kim, Yiyu Hong, Insuk Sohn, Soomin Ahn, Seok-Hyung Kim, Kee-Taek Jang
Cancers.2024; 16(10): 1900. CrossRef - How secure can we expect the surveillance policies to be after the implementation in T1 polyps with carcinoma?
Cristina Mateos Sanchez, Elvira Quintanilla Lazaro, Luis Ramon Rabago
World Journal of Gastrointestinal Endoscopy.2024; 16(9): 502. CrossRef - Comparative prediction of lymph node metastasis in pT1 colorectal cancer among Western and Japanese guidelines
Fumiaki Tanino, Ken Yamashita, Shin Morimoto, Yudai Takehara, Noriko Yamamoto, Yuki Kamigaichi, Tomoyuki Nishimura, Hidenori Tanaka, Hidehiko Takigawa, Yuji Urabe, Toshio Kuwai, Fumio Shimamoto, Shiro Oka
Frontiers in Oncology.2024;[Epub] CrossRef - The risk factors of lymph node metastasis in early colorectal cancer: a predictive nomogram and risk assessment
Jiahui Xu, Fan Yin, Linlin Ren, Yushuang Xu, Congcong Min, Peng Zhang, Mengyu Cao, Xiaoyu Li, Zibin Tian, Tao Mao
International Journal of Colorectal Disease.2024;[Epub] CrossRef - Comment on " Positive fecal immunochemical test results are associated with non-colorectal cancer mortality"
Yong Eun Park
The Korean Journal of Internal Medicine.2023; 38(2): 264. CrossRef - Long-term outcomes after endoscopic versus surgical resection of T1 colorectal carcinoma
Hyun Jin Bae, Hoyeon Ju, Han Hee Lee, Jinsu Kim, Bo-In Lee, Sung Hak Lee, Daeyoun David Won, Yoon Suk Lee, In Kyu Lee, Young-Seok Cho
Surgical Endoscopy.2023; 37(2): 1231. CrossRef - Comparative Cost Analysis Between Endoscopic Resection and Surgery for Submucosal Colorectal Cancer
Soo Min Noh, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, In Ja Park, Seok-Byung Lim, Jeong-Sik Byeon
Diseases of the Colon & Rectum.2023; 66(5): 723. CrossRef - Incidence of colonoscopy-related perforation and risk factors for poor outcomes: 3-year results from a prospective, multicenter registry (with videos)
Jieun Lee, Yoo Jin Lee, Jong Won Seo, Eun Soo Kim, Sung Kook Kim, Min Kyu Jung, Jun Heo, Hyun Seok Lee, Joon Seop Lee, Byung Ik Jang, Kyeong Ok Kim, Kwang Bum Cho, Eun Young Kim, Dae Jin Kim, Yun Jin Chung
Surgical Endoscopy.2023; 37(8): 5865. CrossRef - Usage trends of colorectal endoscopic submucosal dissection according to hospital types based on nationwide claims data
Ji Eun Na, Bohyoung Kim, Sung Hoon Jung, Arum Choi, Sukil Kim, Tae-Oh Kim
Medicine.2023; 102(43): e35514. CrossRef - Risk and Time Pattern of Recurrences After Local Endoscopic Resection of T1 Colorectal Cancer: A Meta-analysis
Hao Dang, Nik Dekkers, Saskia le Cessie, Jeanin E. van Hooft, Monique E. van Leerdam, Philip P. Oldenburg, Louis Flothuis, Jan W. Schoones, Alexandra M.J. Langers, James C.H. Hardwick, Jolein van der Kraan, Jurjen J. Boonstra
Clinical Gastroenterology and Hepatology.2022; 20(2): e298. CrossRef - Emergence of a New Optical Marker for Colorectal Neoplasms: To What Extent Should We Accept It?
Han Hee Lee
Clinical Endoscopy.2022; 55(2): 315. CrossRef - Deep Submucosal Invasion Is Not an Independent Risk Factor for Lymph Node Metastasis in T1 Colorectal Cancer: A Meta-Analysis
Liselotte W. Zwager, Barbara A.J. Bastiaansen, Nahid S.M. Montazeri, Roel Hompes, Valeria Barresi, Katsuro Ichimasa, Hiroshi Kawachi, Isidro Machado, Tadahiko Masaki, Weiqi Sheng, Shinji Tanaka, Kazutomo Togashi, Chihiro Yasue, Paul Fockens, Leon M.G. Moo
Gastroenterology.2022; 163(1): 174. CrossRef - Utility of artificial intelligence with deep learning of hematoxylin and eosin-stained whole slide images to predict lymph node metastasis in T1 colorectal cancer using endoscopically resected specimens; prediction of lymph node metastasis in T1 colorecta
Joo Hye Song, Yiyu Hong, Eun Ran Kim, Seok-Hyung Kim, Insuk Sohn
Journal of Gastroenterology.2022; 57(9): 654. CrossRef - Endoscopic diagnosis and treatment of early colorectal cancer
Seung Wook Hong, Jeong-Sik Byeon
Intestinal Research.2022; 20(3): 281. CrossRef - Long-term prognosis of curative endoscopic submucosal dissection for early colorectal cancer according to submucosal invasion: a multicenter cohort study
Jongbeom Shin, Eun Ran Kim, Hyun Joo Jang, Dong Hoon Baek, Dong-Hoon Yang, Bo-In Lee, Kwang Bum Cho, Jin Woong Cho, Sung-Ae Jung, Su Jin Hong, Bong Min Ko, Jung-Won Jeon, Weon Jin Ko, Sun Moon Kim, Young Dae Kim, Kim Chan Gyoo, Gwang Ho Baik, In Kyung Yoo
BMC Gastroenterology.2022;[Epub] CrossRef - Artificial intelligence-based colorectal polyp histology prediction using narrow-band image-magnifying colonoscopy: a stepping stone for clinical practice
Ji Young Chang
Clinical Endoscopy.2022; 55(5): 699. CrossRef
- Artificial Intelligence Models May Aid in Predicting Lymph Node Metastasis in Patients with T1 Colorectal Cancer
- 7,365 View
- 188 Download
- 23 Web of Science
- 23 Crossref
- Inflammatory bowel diseases
- Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
- Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
- Intest Res 2020;18(1):85-95. Published online July 19, 2019
- DOI: https://doi.org/10.5217/ir.2019.00055
-
Abstract
PDFSupplementary MaterialPubReaderePub
- Background/Aims
Patients with inflammatory bowel disease (IBD) are usually hospitalized because of aggravated gastrointestinal symptoms. Many clinicians empirically advise these patients to fast once they are admitted. However, there has been no evidence that maintaining a complete bowel rest improves the disease course. Therefore, we aimed to investigate the effects of fasting on disease course in admitted patients with IBD or intestinal Behçet’s disease.
Methods
A total of 222 patients with IBD or intestinal Behçet’s disease, who were admitted for disease-related symptoms, were retrospectively analyzed. We divided them into 2 groups: fasting group (allowed to take sips of water but no food at the time of admission) and dietary group (received liquid, soft, or general diet).
Results
On admission, 124 patients (55.9%) started fasting and 98 patients (44.1%) started diet immediately. Among patients hospitalized through the emergency room, a significantly higher proportion underwent fasting (63.7% vs. 21.4%, P<0.001); however, 96.0% of the patients experienced dietary changes. Corticosteroid use (P<0.001; hazard ratio, 2.445; 95% confidence interval, 1.506–3.969) was significantly associated with a reduction in the disease activity score, although there was no significant difference between the fasting group and the dietary group in disease activity reduction (P=0.111) on multivariate analysis.
Conclusions
In terms of disease activity reduction, there was no significant difference between the fasting and dietary groups in admitted patients with IBD, suggesting that imprudent fasting is not helpful in improving the disease course. Therefore, peroral diet should not be avoided unless not tolerated by the patient. -
Citations
Citations to this article as recorded by- Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective
Lingxi Qin, Wenliang Lv
Nutrition Journal.2025;[Epub] CrossRef - Immunomodulatory effects of calorie restriction and its mimetics: A new potential therapeutic approach for autoimmune diseases
Monokesh K. Sen, Eileen Liao, Duan Ni, Anjie Ge, Laura Piccio
Pharmacological Reviews.2025; 77(4): 100063. CrossRef - Outcomes of dietary management approaches in active ulcerative colitis: A systematic review
Abigail Marsh, Sophie Rindfleish, Kalina Bennett, Anthony Croft, Veronique Chachay
Clinical Nutrition.2022; 41(2): 298. CrossRef - Effect of Ramadan intermittent fasting on inflammatory markers, disease severity, depression, and quality of life in patients with inflammatory bowel diseases: A prospective cohort study
Mohamed Negm, Ahmed Bahaa, Ahmed Farrag, Rania M. Lithy, Hedy A. Badary, Mahmoud Essam, Shimaa Kamel, Mohamed Sakr, Waleed Abd El Aaty, Mostafa Shamkh, Ahmed Basiony, Ibrahim Dawoud, Hany Shehab
BMC Gastroenterology.2022;[Epub] CrossRef - Circadian Influences of Diet on the Microbiome and Immunity
Danping Zheng, Karina Ratiner, Eran Elinav
Trends in Immunology.2020; 41(6): 512. CrossRef
- Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective
- 14,734 View
- 276 Download
- 6 Web of Science
- 5 Crossref
First
Prev
